Contribution to the management of gastrointestinal tumors in dogs and cats by Terragni, Rossella
 
 
 
 
 
 
 
 
Contribution to the management of 
gastrointestinal tumors in dogs and 
cats 
 
 
 
 
Rossella Terragni 
 
Supervisors: Prof. Dr. Jimmy Saunders, Prof. Dr. Massimo Vignoli 
 
A dissertation submitted to Ghent University in partial fulfillment of the requirements 
for the degree of Doctor of Veterinary Medicine. 
 
Academic year: 2016-2017 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contribution to the management of gastrointestinal tumors in dogs and cats 
Rossella Terragni 
Department of Medical Imaging and Small Animal Orthopaedics 
Faculty of Veterinary Medicine 
Ghent University  
 
 
 
 
 
 
 
 
 
No part of this work may be reproduced in any form without permission of the author. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	5	
TABLE OF CONTENTS 
 
List of abbreviations         7 
 
CHAPTER I: GENERAL INTRODUCTION  
 1. Anatomy of the stomach and intestines	 	 	 	 																											10									
2. Gastrointestinal tumours in dogs and cats     17 
3. Diagnosis of gastrointestinal tumours: clinico-pathological parameters  20 
4. Diagnosis of gastrointestinal tumours: medical imaging    23 
5. References          33 
 
CHAPTER II: SCIENTIFIC AIMS      39 
 
CHAPTER III: EGFR, HER-2 and KRAS IN CANINE GASTRIC 
EPITHELIAL TUMORS: COMPARATIVE ONCOLOGY  
1. Abstract          44 
2. Introduction         44 
3. Materials and methods       46 
4. Results          49 
5. Discussion          54 
6. References          58 
 
CHAPTER IV: IS SERUM TOTAL LDH EVALUATION ABLE TO 
DIFFERENTIATE BETWEEN ALIMENTARY LYMPHOMA AND 
INFLAMMATORY BOWEL DISEASE IN A REAL WORLD CLINICAL 
SETTING? 
1. Abstract          64 
2. Introduction         65 
3. Materials and methods       66 
4. Results          69 
5. Discussion          78 
6. References          81 
 
CHAPTER V: STOMACH WALL EVALUATION USING HELICAL HYDRO-
COMPUTED TOMOGRAPHY 
1. Abstract          86 
2. Introduction         86 
3. Materials and methods       87 
4. Results          88 
5. Discussion          94 
6. References          96 
 
CHAPTER VI: GENERAL DISCUSSION   
1. Discussion         98 
2. Future research studies       107 
3. References          108 
 
Summary           114 
 
	6	
Samenvatting          118 
 
Curriculum vitae         122 
 
Bibliography            
 Publications in peer-reviewed scientific journals    124 
Research communications presented during scientific meetings             126 
Posters          130 
 
Acknowledgements         133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	7	
 
List of abbreviations 
 
AC   Adenocarcinoma 
AFP   Alpha-fetoprotein 
AL   Alimentary lymphoma 
ALP   Alkaline phosphatase 
ANOVA   Analysis of variance 
AUC   Area under the curve 
BSC   Body condition score 
CBC   Complete blood count 
CDH1   E-cadherin-encoding gene 
CEA   Carcinoembryonic antigen  
CG   Contrast gastrography 
CRP   C-reactive protein 
CT   Computed tomography 
CTC   Computed tomography colonography  
CTE   Computed tomography enterography 
CTEc   Computed tomography enteroclysis 
CV   Coefficient of variation 
DCG   Double-contrast gastrography 
DV   Dorsoventral 
E-cad   E-cadherin  
EGFR   Epidermal growth factor receptor 
EUS   Endoscopic ultrasonography or endosonography 
EGC   Early gastric cancer 
HER   Human epidermal receptor 
18FDG   Fludeoxyglucose F 18  
FISH   Fluorescent in situ hybrisation    
FNA   Fine needle aspiration 
GC   Gastric cancer 
GEJ   Gastro-oesophageal junction  
GI   Gastrointestinal 
GIST   Gastrointestinal stromal tumor 
	8	
HHCT   Helical hydro-computed tomography 
HHM   Humoral hypercalcemia of malignancy  
HMGB1  High-mobility group B1 proteins 
IBD   Inflammatory bowel disease 
IHC   Immunohystochemistry 
LDH   Lactate dehydrogenase 
LL   Left lateral 
LR   Likelihood ratio 
MALT   Mucosa associated lymphoid tissue 
MPR   Multiplanar reconstruction 
MRE   Magnetic resonance enterography 
MRI   Magnetic resonance imaging 
NPV   Negative predictive value 
PET/CT  Positron emission tomography/computed tomography  
18FDG-PET/CT Positron emission tomography with fludeoxyglucose F 18 
PG   Pneumogastrography 
PPV   Positive predictive value 
PTHrP   Parathyroid hormone-related peptide 
ROC   Receiver operating characteristics 
RL   Right lateral 
SAA   Serum amyloid A 
SC   Serum chemistry 
SE   Standard error 
sTK   Serum thymidine kinase activity  
TK1   Thymidine kinase 1   
TNF-α   Cytokine tumor necrosis factor-α 
TNM   Tumour node metastasis 
xURL   Fold of upper reference limit 
US   Ultrasonography 
VD   Ventrodorsal 
 
 
 
 
	9	
 
 
 
 
 
 
 
 
CHAPTER I 
 
GENERAL INTRODUCTION 
 
 
 
Diagnostic imaging and endoscopic finding in dogs and cats with 
gastrointestinal tumors: a review 
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1. Anatomy of the stomach and intestines 
The stomach (ventriculus, gaster) 
Curvatures and surfaces of the stomach 
The stomach possesses visceral and parietal surfaces, and greater and lesser 
curvatures. The visceral surface (facies visceralis) presents a convex outer surface 
that faces mainly dorsally, but also caudodextrally.  The parietal surface (facies 
parietalis) faces to the left and cranially as well as ventrally. The greater curvature 
(curvatura ventriculi major) forms the convex border of the stomach. The lesser 
curvature (curvatura ventriculi minor) forms the concave border of the stomach. 
 
Regions of the Stomach 
The cardiac part (pars cardiaca) of the stomach is the portion that blends with the 
esophagus. The opening into the stomach is the ostium cardiacum. 
The fundus of the stomach (fundus ventriculi) is the rather large blind outpocketing 
located to the left and dorsal to the cardia. On the left the cardiac notch (incisura 
cardiaca) is formed between the cardia and the bulging fundic part.  
 
 
 
Fig 1. Longitudinal section of the stomach and proximal portion of the duodenum. 
(From Evans HE, de Lahunta A: Miller’s anatomy of the dog, ed 4, St Louis, 2013, 
Saunders/Elsevier.)  
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The body of the stomach (corpus ventriculi) is the large middle portion of the organ. 
It extends from the fundus on the left to the pyloric part on the right. The pyloric part 
(pars pylorica) is approximately the distal third of the stomach as measured along the 
lesser curvature from the angular notch to the duodenum. The initial two-thirds is 
thin-walled and expanded to form the pyloric antrum (antrum pyloricum). The distal 
third is contracted and bent. The pylorus (pylorus) is largely surrounded by a thick, 
double muscular sphincter at the entrance to the duodenum. This forms the narrowest 
part of the cavity of the stomach. The lumen of the pylorus is the ostium pyloricum. 
The pyloric canal (canalis pyloricus) is the short narrow segment between the pyloric 
antrum and the pylorus. 
	
Coats of the Stomach 
The serous coat (tunica serosa) completely covers the stomach except for an 
extremely narrow line on the distal half of the greater curvature. The serosa of the 
stomach is extremely thin and elastic. It adheres closely to the stomach musculature 
by a scanty amount of subserous connective tissue, the tela subserosa. 
The muscular coat (tunica muscularis) of the stomach consists essentially of an outer 
longitudinal and an inner circular layer of smooth muscle fibers. The outer 
longitudinal layer (stratum longitudinale) is continuous with the essentially outer 
longitudinal layers of both the duodenum and the esophagus. As the longitudinal 
fibers cover the pyloric portion they are particularly thick on the sides between the 
curvatures. The inner circular layer (stratum circulare) of the stomach is more 
complete and specialized than is the longitudinal layer. At the cardia the circular layer 
is thickened to form the small cardiac sphincter (m. sphincter cardiae). Surrounding 
the pyloric canal, the inner circular layer is well developed. The pylorus, which opens 
into the duodenum, is also surrounded by a circular muscle termed the pyloric 
sphincter (m. sphincter pylori). The submucous coat (tela submucosa) consists of a 
dense but thin elastic layer of areolar tissue that more firmly attaches to the mucosa 
than to the muscularis. It contains the finer branches of the gastric vessels and nerves. 
The mucous coat (tunica mucosa) in carnivores is entirely glandular. It consists of a 
columnar surface epithelium, a glandular lamina propria, and a lamina muscularis 
mucosae consisting of muscular fibers which may be irregularly interwoven or. The 
normal color of the mucosa in the body and fundus of a fresh stomach is pink to 
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grayish red. In the pyloric region it is lighter in color. The color varies with the 
amount of contained blood, as well as the freshness of the material. 
	
Glands of the Stomach 
The glands of the stomach are known as the gastric glands (glandulae gastricae). 
They are branched tubular glands with necks and bodies that reach nearly to the 
lamina muscularis 
mucosae. Three types of gastric glands are recognized in the dog. These are the 
cardiac glands, the gastric glands proper, and the pyloric glands. The cardiac glands 
(glandulae cardiacae), are found in a narrow zone around the cardia. 
The gastric glands proper (glandulae gastricae [propriae]), or fundic glands, 
occupy approximately two thirds of the gastric mucosa. The pyloric glands 
(glandulae pyloricae) are found in the pyloric part of the stomach. The difference 
between the various gland zones is in the type of cells they contain, and therefore in 
the nature of the secretion they produce.  The glands of the cardiac and pyloric 
regions function mainly to produce mucus; the proper gastric glands produce 
hydrochloric acid indirectly and the enzyme pepsin.  
As in most other areas of the alimentary canal, lymph nodules are scattered 
throughout the mucosa of the stomach. Some of these extend through the lamina 
muscularis mucosae into the submucosa. 
 
The intestines 
 
Small intestine 
The small intestine (intestinum tenue) extends from the pylorus of the stomach to the 
ileocolic orifice leading into the large intestine. The small intestine consists of three 
main parts, the relatively fixed and short proximal loop, or duodenum; the freely 
movable, long, middle and distal portions, the jejunum; and the very short terminal 
part, the ileum. 
 
Duodenum 
The duodenum is the first and most fixed part of the small intestine. For descriptive 
purposes the duodenum is divided into four portions and two flexures. The cranial 
portion (pars cranialis) of the duodenum is short between the pylorus and cranial 
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duodenal flexure. It arises from the pylorus and almost immediately turns acutely to 
the right and caudally as the cranial duodenal flexure (flexura duodeni cranialis) 
that runs essentially caudally. The descending portion (pars descendens) of the 
duodenum, approximately 15 cm long, runs caudally from the cranial portion nearly 
to the pelvic inlet. The caudal duodenal flexure (flexura dudeni caudalis) is between 
the descending and transverse parts of the duodenum. The transverse portion (pars 
transversa [pars caudalis]) of the duodenum connects the descending and ascending 
portions from right to left and is approximately 5 cm long. The ascending portion 
(pars ascendens) of the duodenum runs obliquely cranially and to the left from the 
transverse part. Then it makes a sweeping curve ventrally to form the 
duodenojejunal flexure (flexura duodenojejunalis). At this flexure the jejunum 
continues the duodenum ventrally, caudally, and to the left, and enters into the 
formation of numerous coils and kinks (festoons), which constitute most of the 
intestinal mass. 
 
  
 
Fig 2. Intestines of a cat: Removal of the jejunum reveals the duodenum, which 
begins at the pylorus and continues caudally as the descending duodenum along the 
right side of the abdomen, where it is in contact with the parietal peritoneum. The 
descending duodenum runs nearly to the pelvic inlet, where it turns, forming the 
caudal duodenal flexure moving from right to left. Then it continues cranially as the 
ascending duodenum. (From Smith BJ: Gastrointestinal organs and spleen. In Canine 
anatomy, Philadelphia, 1999, Lippincott Williams & Wilkins.) 
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Jejunum and Ileum 
The jejunum and ileum compose the remainder and the majority of the small intestine 
with the jejunum being the longest portion. The jejunum begins at the duodenojejunal 
flexure, and the ileum ends by opening into the initial portion of the ascending colon 
as the ileal papilla (papilla ilealis) with an ileal orifice (ostium ileale) and an 
associated circular sphincteric muscle (m. sphincter ilex). The ileum of the dog is 
approximately the last 15 cm of the small intestine. 
 
Coats of the small intestine 
The small intestine, like the other parts of the alimentary tract, is composed of 
mucous, submucous, muscular, and serous tunics. 
 
 
Fig 3. The histologic layers of the small intestine of a cat.  
 
The mucous coat (tunica mucosa), throughout the small intestine of the dog, presents 
a free surface that is velvety due to the presence of innumerable intestinal villi (villi 
intestinales). The single-layered epithelial surface cells are of two types. One type 
consists of the columnar cells, which function is absorption, and the other type 
consists of the goblet, mucusproducing cells. The deeper part of the mucosa is 
occupied largely by the intestinal glands (glandulae intestinales) and diffuse 
lymphoid tissue and single nodules. In approximately 22 areas throughout the small 
intestine of the dog the lymphoid nodules are grouped together to form the 
aggregated lymph nodules (nodull lymphatici aggregati). The lamina muscularis 
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mucosae, was found to be three times thicker in the dog than it was on average in the 
other domestic animals studied. It is finally divided into inner circular and outer 
longitudinal layers. The submucous coat (tela submucosa) resembles that of the 
stomach and large intestine. It loosely binds together the mucous and muscular layers. 
The smaller blood vessels, lymphatics, and the submucous nerve plexus are located in 
it. The muscular coat (tunica muscularis) consists of a relatively thin outer 
longitudinal layer (stratum longitudinale) and a thicker inner circular layer (stratum 
circulare). The serous coat (tunica serosa) of the small intestine is composed of the 
peritoneum, which almost completely covers the duodenum.  
 
Large intestine 
 
The large intestine (intestinum crassum) is short and unspecialized. In general, it is a 
simple tube, only slightly larger in diameter than the small intestine and is divided 
into cecum, colon, rectum, and anal canal. It begins at the ileal papilla and ends at the 
anus. 
 
Cecum 
The cecum exists as a diverticulum of the proximal portion of the colon, the 
ascending colon. It is approximately 5 cm long and 2 cm in diameter at its colic end.  
 
 
 
Fig 4. Longitudinal section through ileocolic orifice of the canine ileocolic junction, 
ventral aspect. B, The feline cecum is a short, conelike structure with no 
compartmentalization and rarely contains gas. (A from Evans HE, de Lahunta A: 
Miller’s anatomy of the dog, ed 4, St Louis, 2013, Saunders/Elsevier. B from Thrall 
DE, editor: Textbook of veterinary diagnostic radiology, ed 5, Philadelphia, 2007, 
Saunders/Elsevier. Reprinted from O’Brien TR: Radiographic diagnosis of abdominal 
disorders in the dog and cat, Davis, CA, 1981, Covell Park Veterinary.) 
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It irregularly tapers to the rather blunt apex (apex ceci), which is less than 1 cm in 
diameter and usually points caudoventrally. The large middle portion of the organ 
may be referred to as the body (corpus ceci). The only communication of the cecum 
is with the beginning of the ascending colon by means of the cecocolic orifice (ostium 
cecocolicum). 
This opening lies approximately 1 cm from the ileocolic orifice. The cecal sphincter 
(m. sphincter ceci) is a specialization of the inner circular muscular coat that guards 
the cecocolic orifice. At the apical end of the body beyond its attachment to the ileum 
extends the single or double ileocecal fold (plica ileocecalis. 
 
Colon 
The colon is divided into ascending, transverse, and descending portions and their 
connecting flexures. The ascending colon (colon ascendens) begins at the ileal 
ostium, runs cranially, and ends at the right-angled right colic flexure. It usually is 
approximately 5 cm long, but this varies greatly. The transverse colon (colon 
transversum) forms an arc that runs from right to left cranial to the root of the 
mesentery. It is approximately 7 cm long. The descending colon (colon descendens) 
is the longest segment of the colon. It extends from the left colic flexure to a 
transverse plane passing through the pelvic inlet, where it is continued by the rectum 
without demarcation. It is approximately 
12 cm long and usually quite straight.  
 
Rectum 
The rectum begins at the pelvic inlet, where it is continuous cranially with the 
descending colon; it ends ventral to the second or third caudal vertebra, at the 
beginning of the anal canal. It is straight, approximately 5 cm long, and 3 cm in 
diameter. 
The most prominent feature of the rectal mucosa is the presence of approximately 100 
solitary lymph nodules (lymphonoduli solitarii). These nodules are each 
approximately 3 mm in diameter and 1 mm high. The free surface of each is 
umbilicated, forming a crater, or rectal pit.  
 
Coats of the Large Intestine 
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Except for the terminal part, all of the large intestine has the usual four coats as found 
in the small intestine. These are the mucous, submucous, muscular, and serous tunics, 
or coats. 
The mucous coat (tunica mucosa) contains numerous solitary lymph nodules that are 
most numerous in the rectum. The mucosa of the large intestine contains many folds 
and depending on the type of contraction, these plicae are either longitudinal or 
circular. The intestinal glands (glandulae intestinales) of the large intestine are 
longer, straighter, and richer in goblet cells than are those of the small intestine. They 
are lined by a columnar epithelium. The lamina muscularis mucosae consists of 
muscle fibers that are poorly arranged in two strata. The submucous coat (tela 
submucosa) does not differ appreciably from that of the small intestine. Many of the 
solitary lymph nodules are located partly within it. This tunic contains the submucous 
nerve plexuses and many vessels in the meshes of loose connective tissue. The 
muscular coat (tunica muscularis) is uniform in thickness. The stratum longitudinale 
is not concentrated in muscular bands (taenia). The stratum circulare of the large 
intestine resembles that of the small intestine, except that it is thicker. Its caudal 
portion forms the internal anal sphincter muscle. The serous coat (tunica serosa) 
resembles that of the small intestine. It covers the colon, cecum, and much of the 
rectum, as the visceral peritoneum. The anal canal and the caudal portion of the 
rectum are retroperitoneal.  
 
2. Gastrointestinal tumors in dogs and cats 
 
Gastric tumors are uncommon in dogs and cats representing less than 1% of all 
malignancies.1 The mean age of affected animals is 8 years (15 years for 
leiomyomas), with a 2:1 male-to-female ratio.2 A higher incidence of gastric 
carcinoma has been reported in Belgian shepherd dogs, Collies, Staffordshire bull 
terriers and Siamese cats, implying a strong genetic component.3,4 The low prevalence 
of the disease is more influenced by breed popularity in the different countries and 
may have resulted in an underestimation of the incidence in the uncommon breeds.5 A 
strong environmental component has been suggested in dogs because experimental 
long-term administration of nitrosamines may induce gastric carcinoma.6 Several 
epidemiological studies in humans support a positive association between gastric 
cancer risk and nitrite and nitrosamine. Humans are exposed to a wide range of 
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nitrosamines and nitrosamides from diet (cured meat products, dried salted fish, 
smoked preserved food, pickled and salty preserved food), tobacco smoking, work 
place and drinking water. Certain dietary characteristics, including high sodium intake 
or low product (vegetables/fruit) consumption are recognized risk factors for human 
GC. Many studies have also examined genetic changes related to GC development 
and progression in people. While in humans Helicobacter pylori is an influential 
factor in the carcinogenesis of gastric tumors, causing an epithelium damage, 
association has not been documented in dogs and cats.7 
Patients with gastric tumors usually present themselves with a history of progressive 
vomiting, hematemesis, melena, anorexia and weight loss. Chronic vomiting is caused 
by neoplastic stenosis, gastric ulceration and/or gastric motility disorders. Weight loss 
may be a result of anorexia, malabsorption and maldigestion, loss of protein and 
blood from an ulcer, and/or generalized tumor cachexia. Occult blood in the feces 
may be detected. The clinical signs can last from weeks to months.7 Laboratory 
abnormalities may include panhypoproteinemia, microcytic hypochromic anemia 
related to chronic gastrointestinal blood loss and malabsorption, elevated liver 
enzymes due to hepatic metastasis or obstruction of the common bile duct.7 
Both leiomyoma and leiomyosarcoma may present with paraneoplastic 
hypoglycemia8,  
The majority of canine gastric tumors are malignant and epithelial in origin and affect 
the distal two-thirds of the stomach. Adenocarcinoma (AC) accounts for 70–80% of 
canine stomach tumors.9 They often appear scirrhous (firm, white serosa) and have 
been termed linitis plastica (leather bottle) because of their firm, nondistensible 
texture. In adenocarcinoma, lesions can be diffusely infiltrative and expansile, often 
with a central crater and ulceration (Fig. 5), or may look more polypoid.10 The 
prognosis in cases of gastric carcinoma is poor. Furthermore, 70–90% of gastric 
carcinomas have metastasized by the time of diagnosis and underwent euthanasia.5 
The most common sites reported for metastases are the regional lymph nodes, with 
others being the omentum, duodenum, liver, pancreas, spleen, oesophagus, adrenal 
glands, and lungs.5  
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Fig 5. Resected AC of the stomach in a Golden Retriever. The tumour was lying close 
to the pyloric sphincter. Note the large, perforating ulcer (right image).   
 
Leiomyosarcoma is often bulky, tends to affect the entire thickness of the gastric wall 
and most commonly occurs at the pyloric antrum. 
Lymphoma is the most common gastrointestinal (GI) neoplasm in the cat and may be 
solitary in the stomach or one component of a systemic involvement. In the post-
feline leukaemia virus era, the total incidence of feline leukaemia virus-related 
lymphoma has decreased but there has been an increase in the incidence of non-feline 
leukaemia virus lymphoma, particularly in the alimentary tract.11 Lymphocytic-
plasmacytic enterocolitis has been suggested as a precursor to feline intestinal 
lymphoma, but this suggestion has not been supported by other studies. Dietary 
allergies and chronic inflammatory bowel disease have been postulated as precursors 
to intestinal lymphoma but associations have not been documented.11 
Other malignancies include mast cell tumor (mastocytoma), extramedullary 
plasmacytoma, fibrosarcoma7 and, very rarely, gastric carcinoid. Metastases may 
reach the stomach by lymphatic or blood vessels. Benign stomach tumors are much 
less common. Typically, gastric adenomas and leiomyomas are solitary incidental 
findings located near the cardia.8 A diffuse extension and/ or malignant 
transformation is rare, but possible. Final diagnosis has to be made with 
histopathology. 
Intestinal tumors in dogs and cats represent less than 10% of all malignancies. In cats 
these tumors are located especially in the small bowel; lymphoma is the most 
recurring type, followed by carcinoma, leiomyosarcoma and mastocytoma.12 
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In dogs, intestinal tumors are mostly located in the large intestine, like in men. 
Lymphoma is the most common type. A male predisposition has been reported in both 
dogs and cats it, with a mean age of 9-10 years. Breed predisposed are: Siamese cat 
(lymphoma and adenocarcinoma) and German shepherd dogs, collies and giant breeds 
(adenocarcinoma).12 
Clinical symptoms depend on the location of the tumor and on the bowel’s lumen 
subocclusion/occlusion. If the neoplasm is located within the small bowel clinical 
syntoms such as vomiting, hematemesis, anorexia and weight loss can occur. If the 
tumor is located in the large intestine tenesmus and hematochezia can be present. In 
case of bowel wall perforation or intussusception abdominal effusion and acute 
abdominal pain could happen. Lymphoma in the bowel is often transmural, while 
adenocarcinoma could be annular or pedunculated. At the time of diagnosis, often 
metastasis or carcinomatosis are present.12 Other bowel tumors are carcinoid, 
extramedullary plasmacytoma, mastocytoma, leiomyosarcoma and gastrointestinal 
stromal tumors. Adenomatous polips are located in the duodenum in cats and in the 
rectum in dogs.12 
 
3. Diagnosis	of	gastrointestinal	tumors:	clinico-pathological	parameters	
 
In human medicine the use of tumour biomarkers is considered standard practice, and 
provides clinicians with diagnostic and prognostic information. For tumour markers 
the priority is to identify true positive cases. Low-invasive biomarkers for obtaining 
diagnostic and prognostic information may have considerable importance in 
determining the treatment strategy for patients with neoplastic disease. Several 
blood-based biomarkers, such as carcinoembryonic antigen (CEA) and alpha-
fetoprotein (AFP), have been identified as low-invasive biomarkers in human 
oncology. 
Identifying biomarkers for canine neoplastic diseases is important with respect to 
human oncology as well. Human and canine spontaneous tumours share many 
essential biological and clinical features, such as their genetics, histopathological 
morphology, and malignant behaviours to invade and metastasise to other organs. 
Canine spontaneous tumours have an additional unique feature of maintaining the 
tumour microenvironment, including tumour heterogeneity, intact immune system, 
abnormal vasculature, and intratumoral hypoxic gradient, whereas conventional 
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mouse xenograft models lack these features. Given the similarities and unique 
features, canine spontaneous tumours have the potential to be useful models in 
biomarker research; and thus, developing biomarkers for canine neoplastic diseases 
might help toward the discovery of novel biomarkers for human neoplastic 
diseases.13 
The measurement of serum enzyme lactate dehydrogenase (LDH) as an initial 
screening for differentiating patients with different cancers (i.e. not only for 
lymphoma) and patients with non-oncological diseases has been used in dogs, but has 
not produced convincing results.14 On the other hand, serum LDH levels 
demonstrated a prognostic value in canine lymphoma recurrence15 and an LDH 
increase has been correlated with a worse prognosis in feline lymphoma, similar to 
the results observed in humans.16 Therefore, assessing serum total LDH in cats as a 
possible marker for alimentary lymphoma (AL) may play an important role in 
differentiating between AL and a non-neoplastic gastrointestinal disease such as 
inflammatory bowel disease (IBD).  
In Veterinary medicine many targets in addition to LDH have been investigated as 
serum biomarkers for canine lymphoma. Tumor products alpha-fetoprotein (AFP) and 
microRNAs; biochemical enzymes corticosteroid-induced alkaline phosphatase 
(ALP); cytokine tumor necrosis factor-α (TNF-α); metabolic profiling by gas 
chromatography; leakage enzymes thymidine kinase 1 (TK1) and high-mobility group 
B1 proteins (HMGB1); fucosylated serum proteins as well as serum proteins serum 
amyloid A (SAA), C-reactive protein (CRP), and haptoglobin have been evaluated. 
Targets were generally selected as tumor-specific products or as participants in 
important disease-related pathways. Only TK1, CRP, and haptoglobin have resulted 
in a commercially available biomarker test.13 
The thymidine kinases are enzymes that convert deoxythymidine to deoxythymidine 
monophosphate and have a function in DNA synthesis. Rapidly proliferating cells 
will have higher levels of thymidine kinase. Serum thymidine kinase activity (sTK) is 
a useful tumour marker in humans, dogs, and cat with utility as a prognostic indicator 
in lymphoma.17 
MicroRNAs (miRNAs), a class of short-noncoding RNAs, play indispensable roles 
in tumorigenesis by controlling the differentiation, proliferation, and cell death of 
cancer cells. Cancer cells not only show dysregulation of miRNAs but also release 
these miRNAs into the bloodstream. The levels of circulating miRNAs can 
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accurately reflect the number of tumour cells, response to treatment, clinical stages, 
and tumour grades. In addition, the sequences of mature miRNAs are broadly 
conserved among diverse species. Therefore, circulating miRNAs have a great 
potential to be common diagnostic and prognostic biomarkers for both human and 
canine neoplastic diseases.18 
Increased serum parathyroid hormone-related peptide (PTHrP) concentration is used 
to diagnose humoral hypercalcemia of malignancy (HHM) in humans and animals. A 
commercially available assay for human PTHrP has diagnostic utility in the dog and 
cats.19 
In human oncology, the importance of the EGFR/HER-2/KRAS (Fig. 6) signalling 
pathway in gastric and colorectal cancer tissue is well established. They are protein 
tyrosine kinases located in cell membranes. The deregulation of these has been shown 
to play an important role in tumour initiation, progression and metastasis.20,21 
 
 
Fig 6. ErbB Receptor Tyrosine Kinases: ErbB-1 (EGFR, HER-1), ErbB-2 (HER-2), 
ErbB-3 (HER-3), ErbB-4 (HER-4). 
 
The potential relevance of these molecules as prognostic and predictive markers 
involving the use, in parallel, of in situ hybridization (FISH), and 
immunohistochemistry (IHC) on tissue samples. Fluorescence in situ hybridization 
it’s a cytogenetic procedure wich use fluorescent probes to detect DNA sequences on 
chromosome, for example to diagnose many types of chromosomal abnormalities. 
Because dogs naturally develop spontaneous cancers, in contrast to mouse models, 
they constitute an excellent comparative model for cancer. The pathological and 
behavioural similarities between many spontaneous canine and human tumours make 
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logical to extend investigations onto molecular oncogenesis in dogs. In veterinary 
medicine, EGFR protein expression has been detected in numerous tumour types, 
including canine mammary tumours, primary brain tumours, nasal carcinomas, lung 
carcinomas and osteosarcomas.22,23 
We know from literature that these antigens were recognised by the humanized 
antibodies applied for immunotherapy in human medicine (trastuzumab and 
cetuximab), leading to growth inhibition in canine mammary cancer cell lines. This 
finding supports the development of novel targeted therapies and adjuvant strategies 
for the treatment of EGFR/ HER-2-expressing canine cancers.24 
 The expression of EGFR and HER-2 in canine gastric epithelial tumours was 
investigated in dogs, to deepen a role of these receptors in carcinogenesis, especially 
when compared to normal gastric mucosa. Therapeutic targeting of EGFR and HER-2 
could be a promising line of research in canine gastric cancer. EGFR protein 
overexpression in canine and feline intestinal tumors has not been investigated. 
 
4. Diagnosis	of	gastrointestinal	tumors:	medical	imaging	
 
Medical imaging is an essential part of the diagnostic workup of many gastrointestinal 
disorders. 
 
Radiography 
A native radiographic examination of the stomach includes four projections: 
ventrodorsal (VD), dorsoventral (DV), left lateral (LL) and right lateral (RL). Air can 
move in the different part of the stomach and allow to visualize the gastric regions. 
On the lateral view, the axis of the stomach from the fundus throughout the body and 
pylorus is parallel to the ribs. On the VD view of the dog, the cardia, fundus and body 
of the stomach are located to the left of the midline, and the pyloric portion is located 
in the right hemiabdomen. The pyloric sphincter is usually located in the right cranial 
abdominal quadrant around the level of the 10th or 11th rib, usually cranial to the 
pyloric canal. On the VD view of the cat, the stomach is more acutely angled with the 
pylorus located at or near the midline. The normal gastric wall appears smooth and 
uniform and is a few mm thick when fully distended. Rugal folds are more tortuous in 
the non-distended stomach and become more uniform and parallel to the gastric 
curvature as distension increases. In the pyloric antrum, they are small and spiral.25 
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The normal small bowel in survey radiography is smooth, continuosly curving tubes 
or as solid circles or rings. These shapes are produced by contractile activity of the 
smooth muscle. Segmental contractions give rise to spherical shapes, whereas 
peristaltic contractions cause long tubular shapes. In the fasted cat gas is rarely 
present, but in fasted dog 30%-60% of the small bowel content may be gas. The colon 
of the dog and cat is a thin-walled distensible tube that is divided into ascending, 
transverse and descending parts. These division are recognised on survey radiographs 
based on shape, size and location. The shape of the colon is similar to a question 
mark; the junction between the ascending and tranverse colon is the right colic flexure 
and the junction between the tranverse and descending colon is the left colic 
flexure.26,27 
Contrast radiographic studies should always be preceeded by survey radiographs. 
Various contrast radiographic techniques have been described for the stomach such as 
positive-contrast gastrography (CG), using barium or iodinated contrast medium, 
pneumogastrography (PG), using air or another gas, double-contrast gastrography 
(DCG), using a positive contrast followed by gas and low-volume gastrography. 
Small bowel evaluation with contrast medium studies is performed using barium or a 
low-osmolarity iodinated contrast medium by gastric tube or an oral syringing. For 
the large intestine, a barium enema, a pneumocolon or a double contrast enema should 
be used. Contrast studies of the stomach have progressively been replaced by 
endoscopy while contrast studies of the intestinal tract are still barely performed since 
the coming of ultrasonography (US) and endoscopy. 
 
Ultrasonography 
Transabdominal US is the imaging modality of choice for examination of the 
abdomen in veterinary medicine. Endoscopic ultrasonography or endosonography 
(EUS) is useful for studying the stomach and the intestinal wall, but the instruments 
are very expensive and general anesthesia is required. For US in dogs and cats, the 
transducers depending on the size of the animals. A microconvex transducer with a 
frequency range between 5-10 MHz can be used in all animals and may allow 
visualization of all parts of GI tract. For large and giant-breed dogs, a transducer with 
a lower frequency (3.5-5 MHz) may be useful to evaluate the deepest part of the 
stomach. A linear high frequency transducer (7-15 MHz) may be useful to scan the 
complete stomach and bowel in cats and small dogs and to evaluate the superficial 
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ventral aspect and left lateral aspect of the stomach and bowel in all animals. The 
animal should be fasted for 12 hours before the examination so that the stomach is 
empty or contains gas or fluid but no food. Water administration at 10-15 mL/kg will 
enhance visibility of mural pathology and may help overcome air-induced artifacts.28 
The abdomen is usually examined in dorsal decubitus. However, for the stomach, 
because of the presence of gas and fluid, a combination of positions (dorsal, right 
lateral, left lateral recumbency and standing position) may be required to completely 
visualize the stomach wall. Right lateral recumbency is useful for pyloric examination 
and left lateral for the fundus. The echoendoscope (radial and linear multifrequency 
scanners) is similar to a conventional endoscope except that it has an ultrasound 
transducer at its tip; EUS allows visualization of both the inner and outer parts of the 
gastric wall, using high-frequency transducers that can be taken close to the target 
regions. Transducer coupling is either by direct mucosal contact or inflation of a 
water-filled balloon surrounding the transducer (Fig. 7).29 However, up to now, no 
study has assessed the usefulness of EUS in diagnosing gastric disease in dogs and 
cats. 	
 
 
Fig 7. EUS image of the stomach in a dog with gastric adenocarcinoma showing 
complete loss of stomach wall layering. 
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On US, different tumor types can show a similar appearance. Loss of layering and a 
focal thickening are strongly suggestive of a gastric tumor, with a higher sensitivity 
than radiography.30 The thickening of the gastric wall can be generalized or localized, 
symmetrical or asymmetrical, and associated or not with significant loss of motility. 
A focal thickening with normal layered architecture may suggest leiomyoma, 
malignant histiocytosis or a polyp. The gastric carcinoma shows a typically 
asymmetrical, moderate to severe, heterogeneous gastric wall thickening. The normal 
layers are obliterated but may be replaced by three alternating bands referred to as 
pseudolayering. Pseudolayering is visible as a poorly defined, echogenic lining on the 
innermost and/or outermost portions of the gastric wall, separated by a more echoic 
central zone. It most likely correlates with the unevenly layered tumor distribution 
noted histopatologically.31 Myogenic tumors (leiomyoma and leiomyosarcoma) are 
often located in the pyloric region and appear as hypoechoic submucosal masses 
arising from the muscular layer. Leiomyoma usually appear as a homogeneous, small, 
sessile, echoic mass in dogs.32 A large, complex mass with an irregular central cavity 
(representing hemorrhage, necrosis or cystic degeneration) most likely represents a 
leiomyosarcoma.30 It can ulcerate and lead to wall perforation.32 Canine and feline 
gastric lymphoma usually show circumferential, transmural thickening associated 
with diffuse loss of normal wall layering and reduced wall echogenicity, localized 
decreased motility and moderate regional lymphadenopathy.28,33 Lymphoma can also 
show a focal hypoechoic eccentric mass.30 The gastric carcinoma is often associated 
with regional lymphadenopathy. In gastric carcinoma, lymph nodes have a target 
appearance, with a poorly defined echoic rim and a highly defined echoic center.31 
The US features of malignant histiocytosis, malignant fibrous histiocytoma and 
histiocytic sarcoma have been reported sporadically.34,35 Other tumors, like carcinoid, 
neurilennoma, nerve-sheath tumor, mast cell tumor and hemangiosarcoma, tend to 
appear as poorly defined echoic masses or as a focal thickening with loss of layering. 
There are no specific US features for these tumors.36 
Benign gastric polyps (hyperplastic and adenomatous) are sessile or pedunculated 
nodules that arise from the mucosa and protrude into the gastric lumen. In dogs and 
cats, they may occur as solitary or multiple cauliflower lesions. Occasionally, large 
polyps in the pyloric antrum can cause gastric outflow obstruction. On US, canine 
gastric polyps appear as heterogeneous lesions confined to the mucosa without 
involvement of the submucosal layer. Gastric wall thickening corresponding to wall 
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edema and luminal fluid accumulation associated with reduced gastric motility may 
be observed in animals with large lesions. Gastric polyps can rarely display poorly 
visualized gastric wall layers.37 
Stomach ulcers are a possible complication of gastric tumors. The US findings 
associated with gastric ulceration are focal wall thickening with indistinct wall layers, 
or loss of layering and disruption of the normal mucosal surface in a large ulcer with 
an ulcer crater. It can be a focal accumulation of hyperechoic material on the mucosal 
surface (gas bubbles or blood clots) and decreased motility of the affected wall 
segment (Fig. 8A-E).30 US-guided fine needle aspiration of the GI tract has been 
described.38 
 
 
Fig 8. (A) US of the gastric antrum of a dog with adenocarcinoma. There is irregular 
heterogeneous gastric wall thickening (among arrows) with loss of layering. (B) US 
of a dog with an adenocarcinoma of the lesser curvature and antrum. In the ventral 
portion of the stomach wall there is a pseudolayering pattern, with hypoechogenic 
innermost and outermost parts (arrows), separated by a more echoic central zone 
(asterisk). (C) Longitudinal US view of dog with leiomyosarcoma of the gastric 
antrum. A homogenous, round, hypoechoic mass lesion involving the muscular layer 
of the stomach wall is visible. The mucosa and submucosa are normal. (D) US 
longitudinal image of the gastric fundus and body of a cat with lymphoma of the 
stomach. There is a severe circumferential thickening and complete loss of layering of 
the stomach wall, which is mostly hypoechoic. The wall between the callipers 
measures approximately 2.5 cm. (E) US image at the level of the gastric body of a 
dog. Gastric ulceration is visible as a focal wall thickening with loss of layering and 
disruption of the normal mucosal surface. The ulcer crater is filled with gas (arrow). 
Chapter	I	General	introduction	
28	
 
As in the stomach, intestinal wall thickening is commonly found with inflammatory 
diseases or neoplasia. Nonmalignant diseases tends to induce diffuse, mild to 
moderate wall thickening with preservation of the wall layers. Neoplastic lesion 
characteristically produce more extensile focal thickening or mass lesions with 
distruption or loss of the wall layers. The exception is lymphoma, wich can either 
diffusely infiltrate the bowel or produce mass lesion. In either case there is loss or 
alteration of the wall layers. Wall thickening may be circumferential. The lesion 
usually appears distinctly hypoechoic, ulceration may be present, and regional 
lymphoadenopathy is common. Adenocarcinoma tends to cause circumferential 
thickening of the bowel with loss of wall layering and partial or complete intestinal 
obstruction; usually bowel carcinomas are solitary masses but can spread throught the 
peritoneal cavity.39 Leiomyomas in the bowel are small and have smooth contours, 
instead leiomyosarcomas are generally large, eccentric masses. Mast cell disease can 
produce diffuse wall thickening or a focal mass in cats and dogs. The sonographic 
characteristics of these abnormalities have not been widely reported.39 (Fig .9). 
 
 
Fig 9. (A) US of a dog with intestinal leiomyosarcoma. There is irregular slightly 
heterogeneous intestinal wall thickening (among cursors) with loss of layering. (B) 
Increased in size, hyoechogenic and irregularly outlined metastatic jejunal lymph 
node. (C) US transversal image of a dog with lymphoma of the intestine (jejunum). 
There is a severe circumferential thickening and complete loss of layering of the 
intestinal wall, which is mostly hypoechoic.  
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Endoscopy 
Upper gastrointestinal endoscopy (esophago-gastro-duodenoscopy) is a minimally 
invasive and traumatic procedure that allows direct visualization of the gastric and 
intestinal wall and is associated with low morbidity and mortality.40 A flexible 
endoscope with an insertion tube with 1 m of working length and a tip with a diameter 
between 7-9 mm (< 9.5 mm) is recommended. The accessory/biopsy channel should 
have a minimum diameter of 2.2 mm and the tip should be capable of four-way 
deflection. The tip must be able to retroflex more than 180° in one plane with a small 
radius of curvature. The endoscope must have an inflation system (essential for 
stomach visualization) and a washing lens system. A xenon light source is preferred 
for greater illumination. Suction is necessary to remove secretions and air; biopsy 
forceps should be available for tissue collection. The patient should be fasted for at 
least 12 hours. Water is allowed. If a barium contrast radiographic study has been 
performed, upper endoscopy should be delayed for 24 hours because barium can 
cause serious blockage of the instrument.41 General anesthesia with intubation is 
required for endoscopy. The patient is positioned in left lateral recumbency because 
this position facilitates the evaluation of the pylorus. Lubrication of the endoscope is 
preferred before it is introduced. A mouth gag must be inserted.41 
Gastroduodenoscopy is contraindicated when GI perforation is suspected, the patient 
is inadequately prepared, the patient cannot be anesthetized or the patient has 
coagulation disorders. Complications (overdistension of the stomach, perforation due 
to poor technique, mass rupture and transmission of enteropathogenic organisms) are 
rare.41 Gastric polyps are sessile or pedunculated protuberances of the gastric mucosa 
that do not disappear with maximal inflation. They can be benign (adenomatous 
polyp), malignant (carcinoma) or inflammatory/hyperplastic. Polyps are most 
commonly found in the pyloric region, more often in the antrum. At gastroscopy, 
polyps are generally single, multilobated or grape-like masses that may bleed from an 
eroded surface and may or may not occlude the pyloric orifice.42 Endoscopic surgery 
can be performed to remove polypoid lesions.43 Gastric neoplasms can present with a 
variety of appearances, from raised plaques or masses projecting from the lumen to 
firm, diffusely infiltrating masses invading the stomach wall. They may ulcerate and 
alter the gastric lumen and shape. Ulcers occur more frequently with adenocarcinoma 
and leiomyoma/leiomyosarcoma than with lymphoma. Typically, gastric ulcers have 
raised and thickened margins. The bed of the ulcer blood can be present in the gastric 
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fundus and may indicate the ulcer's presence. Ulcers resulting from gastric 
adenocarcinoma are usually associated with broad areas of induration, while ulcers 
due to leiomyoma are usually crater-like with raised margins. Gastric adenocarcinoma 
is most commonly seen on the lesser curvature of the stomach. It may appear as an 
obvious mucosal mass or with mucosal change of color (from pink to purple) with 
deep pigmentation of the mucosa, ulceration, loss of normal landmarks and rigidity of 
the gastric mucosa.44 Sometimes an AC shows marked proliferative changes with a 
rigid, very dense wall that has completely lost the normal rugal fold architecture. 
Infiltrative neoplasms, such as lymphoma, usually show a diffusely thickened mucosa 
with a markedly increased wall consistency (Fig. 10 A-F). However, they can also 
appear as a mass lesion. Gastric lymphoma can affect either the entire stomach or 
only part of it, and show a mucosa that is often lumpy and friable or, less commonly, 
thick and irregular.41 The indurated mucosa often feels heavy and yields little as the 
endoscope or biopsy forceps contacts it.40 If the mass is in the pylorus, it may occlude 
the pyloric orifice. Leiomyoma usually appear as expansile submucosal masses.42 All 
gastric lesions should be biopsied with endoscopic forceps or cytology brushes and 
multiple samples should be taken for cytology or histopathology. 
Endoscopy is useful only if the tumor is located in the duodenum, terminal portion of 
the ileum, cecum, colon and rectum. The intestinal epithelial neoplasms generally 
seems polypoid or in mass, with irregular tissue or projecting into the lumen. They 
may also have ulcerated or plaque appearance. Lymphoma has an invasive attitude 
and is widespread. Other neoplastic conditions such as leiomyoma, leiomyosarcoma, 
stromal tumors, mast cell tumor and plasmacytoma have not typical endoscopic 
criteria.45 
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Fig 10. (A) Adenomatous polyp in a dog is visible at the gastric antrum. (B) Large 
gastric polyp of the antrum (gastric carcinoma in situ) in a dog with chronic vomiting. 
(C) Gastric antrum grape-like polyps (adenocarcinoma) in a cat with chronic 
vomiting. (D) Gastric ulcer (adenocarcinoma) in a dog with anorexia and weight loss. 
Arrows indicate the neoplastic ulcer's borders that surround the necrotic centre. The 
tumor is located in the gastric body. (E) Gastric carcinoma in a dog. The small 
curvature (asterisk) is extremely thickened and the fundus folds (arrow) are replaced 
by proliferative ulcerated neoplastic tissue. (F) Gastric fundus lymphoma in a cat. 
Arrows indicate fundus rugal folds infiltrated by neoplastic tissue. 
 
Advanced imaging techniques 
Computed Tomography (CT), Positron emission tomography (PET) and Magnetic 
Resonance Imaging (MRI) are used for diagnosis and staging of gastric tumors in 
human, however so far they are no studies in the veterinary literature. The accuracy of 
CT in the diagnosis and staging of gastric cancer in humans improves when helical 
CT of the stomach is performed after the oral administration of water. This procedure, 
which is termed helical hydro-computed tomography (HHCT), is followed by the 
intravenous injection of contrast medium to enhance the image of the gastric wall.46 
 Using computed tomography with water as a negative oral contrast agent and 
intravenous contrast medium, can provide critical information for the diagnosis of 
gastric diseases. In addition, CT can evaluate the involvement of the gastric wall and 
extragastric extent of the disease, as compared with gastroenteroscopy and double-
contrast upper gastrointestinal study. Regarding lesion location and size, enhancing 
and growth patterns, presence of calcification or fat, and involvement of the gastric 
wall and adjacent structures, CT may provide useful information.47 
The water (500 mL) is administered in a routine procedure to obtain gastric distention 
before the patient is laid down on the CT table. The dynamic CT imaging for the 
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gastric lesions is performed in three phases (non-enhanced, arterial, and portovenous). 
Non-enhanced imaging is obtained to provide a baseline for the degree of lesion 
enhancement as well as detecting the hemorrhage, calcification, and fat component of 
the lesion. The arterial phase is obtained 30 seconds after the injection of a dose of 2 
mg/kg of nonionic contrast material at a rate of 2.5 mL/s, using an automated power 
injector. The portovenous phase is obtained 50 s after the contrast injection. The 
contrast-enhanced phases help in assessing the extent of involvement of the stomach, 
differentiating mucosal and submucosal tumors, determining the enhancing and 
growth patterns, and detecting distant metastasis and lymphadenopathy. 47	
The bowel distension is obtained with different CT techniques: CT enteroclysis 
(CTEc), CT enterography (CTE) and CT colonography (CTC). Fasting and intestine 
cleansing are necessary for all the procedures. Negative oral contrast agents like 
lactulose, water, oil emulsion, methylcellulose, polyethylene glycol, mannitol, and 
ultra–low-dose barium with sorbitol are preferred in the assessment of intestinal wall 
enhancement. CT enteroclysis is performed after nasojejunal intubation under 
fluoroscopy; as this process is invasive for patients, CTE is the preferred technique. 
For this 300 mL 20% w/v mannitol is mixed with 1.5 L water. A total of 500 mL of 
mixture is given orally to patients in the first 15 minutes followed by 500 mL in the 
next 15 minutes, then 500 mL in the next 15 minutes. The scan is performed at 50 
minutes with the remaining solution given on the table along with intravenous 
contrast injection to patient. 
For CT colonography an oral administration of either water-soluble iodinated contrast 
medium or a diluted barium sulfate suspension is performed, which is done to tag 
residual bowel content and differentiate from true colonic lesions. Then colon is 
inflated with air or carbon dioxide by using a thin and flexible rectal catheter. 
Intravenous administration of 100 mL of nonionic contrast is performed.48 
Positron emission tomography with fludeoxyglucose F 18 (18FDG-PET/CT) has 
rapidly obtained a foothold in the evaluation of bowel disorders, chiefly in neoplasms 
and inflammatory bowel diseases (IBD). 18FDG-PET imaging relies on the increased 
uptake and metabolism of 18FDG in inflammation, infection, or neoplasm. Combining 
18FDG-PET with CT, both morphologic and functional information regarding disease 
site and activity can be obtained. This imaging technique has been enhanced further 
by combining CTE/CTEc and CTC with 18FDG-PET imaging for the evaluation 
of the small and large bowel, respectively. 18FDG is administered. For PET-CTE, 
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patients drink 1.5 L of mannitol solution over 45 minutes to 50 minutes, whereas for 
PET-CTEc, a nasojejunal tube is inserted up to the proximal jejunum and 1.5 L of 
normal saline is given through it until patients complain of abdominal 
distension/discomfort. The 18FDG-PET/CTE scanning begins 45 minutes to 60 
minutes after injection of 18FDG.  
Two techniques of colonic distension have been described when CTC is combined 
with 18FDGPET imaging: the patients drink 2.5 to 4.0 L of water mixed with 
polyethylene glycol. Patients are asked to drink this slowly over a period of 1 hour, 
and scanning is done 45 minutes to 60 minute after intravenous injection of 18FDG. 
This technique provides adequate colonic distension without the invasiveness of rectal 
injection. Other technique obtained colonic distension by perrectal injection of 2 to 3 
L of tap water.48 
Magnetic resonance imaging–related procedures include routine MR imaging 
abdomen, MR enteroclysis, and MR enterography. MR imaging is now increasingly 
being used for the evaluation of bowel pathology in view of the lack of ionizing 
radiation and superior contrast resolution. The potential disadvantages include longer 
acquisition times, higher cost, and motion artifacts. Motion artifacts can be eliminated 
partially with the use of fast sequences and antispasmodic agents, such as hyoscine, 
which decreases bowel movement. Although MR enteroclysis provides better 
mucosal detail, it involves nasojejunal intubation, which is an invasive procedure and 
involves ionizing radiation during fluoroscopy-guided tube insertion. MR 
enterography (MRE) is currently the preferred technique as it is faster and more 
tolerable. Positive contrast agents are gadolinium-chelates, ferrous/manganese ions, 
milk, blueberry juice, green tea, and ice cream. Negative contrast agents are: 
ferumoxsil oral suspension, oral supermagnetic particles, and perfluorooctyl-bromide. 
Biphasic contrast agents (water-based): water, diatrizoate meglumine, diatrizoate 
sodium salt, mannitol, locust bean gum, low-dose barium, manganese compounds, 
and Macadamia 16 (hydrophilic liquid emollient derived from ethoxylated 
Macadamia oil glycerides).48 
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Gastrointestinal (GI) neoplasia is uncommon in dogs and cats, with gastric tumors 
representing <1% and intestinal tumors <10% of overall neoplasia in these species. GI 
neoplasms tend to be malignant. Early diagnosis of GI neoplasia is challenging 
because of the lack of specificity of the clinical signs. 
 
Clinico-pathological parameters and medical imaging are non-invasive ways that 
provide a diagnosis of GI tumors in dogs and cats. Huge improvements have been 
made the last decennia in the field of biomarkers and diagnostic imaging providing 
new perspectives for diagnosis, prognosis and treatment in veterinary oncology. 
However, to date, only a limited number of studies have made use these opportunities. 
 
Therefore, the aim of this thesis was to provide new insights in the diagnosis of GI 
tumours in dogs and cats allowing an improved diagnosis, prognostic capabilities and 
therapeutic planning. 
 
Specific objectives of this thesis were: 
1. To evaluate EGFR and HER-2 immunohistochemical expression and KRAS 
mutational status in dogs with gastric tumours, as a step to improve the 
treatment of dogs with gastric tumours.  
These epidermal growth factor receptors and analogs correlate with 
prognosis and response to therapy in many human cancers. More in-
depth knowledge of the role of these molecular pathways could 
provide new insights into the treatment of canine gastric tumours but 
also into the evaluation of dogs as a comparative model for human 
cancers. 
 
2. To determine whether an elevation of the total LDH can be used to 
differentiate alimentary lymphoma (AL) from non-neoplastic gastrointestinal 
diseases in cats. 
The clinical presentation of feline AL is quite similar to that of 
inflammatory bowel disease (IBD). It has been suggested that an 
increase in total LDH can be used as a prognostic factor in cats with 
lymphoma. Potentially the total LDH can also be used to help 
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differentiate malignant from non malignant disease presented with 
similar symptoms. 
 
3. To describe and optimize helical hydro-computed tomography (HHCT) in 
dogs and cats and to evaluate its applicability in clinical patients.  
Performing a helical CT after oral administration of water (HHCT) 
should improve the visibility of the gastric wall and allow a more 
accurate diagnosis of gastric tumours in dogs and cats. However, the 
procedure has to be first optimized, as the optimal amount of water had 
to be determined and its feasibility has to be determined. This was 
demonstrated in normal animals, after with its use in clinical patients 
was evaluated. 
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CHAPTER III 
 
EGFR, HER-2 AND KRAS IN CANINE GASTRIC EPITHELIAL 
TUMORS: COMPARATIVE ONCOLOGY 
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1. Abstract  
 
Epidermal growth factor receptor (EGFR or HER-1) and its analog c-erbB-2 (HER-2) 
are protein tyrosine kinases correlated with prognosis and response to therapy in a 
variety of human cancers. KRAS mediates the transduction of signals between EGFR 
and the nucleus, and mutation in this gene have been associated with resistance to 
anti-EGFR drugs. In human oncology, the importance of the EGFR/HER-2/KRAS 
signaling pathway in gastric cancer is well established, and HER-2 testing is required 
before initiating therapy. Conversely, this pathway has never been investigated in 
canine gastric tumours. A total of 19 canine gastric epithelial neoplasms (5 adenomas 
and 14 carcinomas) have retrospectively been evaluated for EGFR/HER-2 
immunohistochemical expression and KRAS mutational status. Five (35.7%) 
carcinomas were classified as intestinal-type and 9 (64.3%) as diffuse-type. EGFR 
was overexpressed (≥1+) in 8 (42.1%) cases and HER-2 (3+) in 11 (57.9%) cases, 
regardless of tumour location or biological behaviour. The percentage of EGFR-
positive tumours was significantly higher in the intestinal-type (80%) than in the 
diffuse-type (11.1%, p = 0.023). KRAS gene was wild type in 18 cases, whereas one 
mucinous carcinoma harboured a point mutation at codon 12 (G12R) (Also know as 
NC_006609.03:c.36G>C following HGVS nomenclature). EGFR and HER-2 may be 
promising prognostic and therapeutic targets in canine gastric epithelial neoplasms. 
As mutation in the KRAS gene has been found, future studies might investigate the 
role of KRAS in gastric tumours further.   Additional studies are necessary to evaluate 
the role of dog as a model for human gastric cancer. 
 
2. Introduction  
 
Gastric tumours are rare in dogs, representing less than 1% of all canine 
malignancies1,2; 70–80% are epithelial adenocarcinomas1. As in humans, canine 
gastric carcinoma is more prevalent in males and is usually fatal2-5. Gastric adenomas 
are mainly incidental findings; they may undergo malignant transformation1. 
In humans, gastric and gastro-oesophageal junction (GEJ) adenocarcinomas are one 
of a major cause of cancer morbidity and mortality worldwide6. 
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Complete surgical resection is the mainstay of treatment for non-metastatic diseases, 
but many patients are not diagnosed until their disease is either locally advanced or 
metastatic and therefore unresectable6. The prognosis in advanced stages is very 
poor7. 
One of the most significant innovative targets in human cancer is the HER family. 
The members of this family, EGFR, c-erbB-2, c-erbB-3 and c-erbB-4 (also known as 
HER-1, HER-2, HER-3 and HER-4, respectively) are normally located in cell 
membranes and consist of an extracellular ligand-binding domain and an intracellular 
domain with tyrosine kinase activity8. The EGF signaling pathway has been studied in 
human cancer patients with particular attention paid to EGFR, HER-2 and their 
activating ligands as the deregulation of these has been shown to play an important 
role in tumour initiation, progression and metastasis7,8. Tumor dependence on specific 
molecular pathways may identify the best target for therapy exploration. Activation of 
the epidermal growth factor receptor (EGFR)-related signaling pathways drives 
numerous cancer-promoting processes, such as cell proliferation, apoptosis inhibition, 
angiogenesis, cell adhesion, and motility and invasion, and also controls the 
development of drug resistance. Therefore, anti-EGFR approaches (antibodies 
directed against the extracellular domain and small inhibitors of the tyrosine kinase 
activity) have been one of the most successful examples of molecular target therapy in 
human solid neoplasias. 
 Aberrant HER-2 expression or function has been implicated in gastric carcinogenesis 
and in other tumor types, including breast, ovarian, salivary gland, prostate and lung 
cancers9. Trastuzumab, a recombinant humanised IgG1k monoclonal antibody 
directed against the HER-2 extracellular domain, has shown an improvement of 
survival in patients with metastatic HER-2 overexpressing gastric cancer7-10, 
providing significant benefits in terms of response rate, median progression-free 
survival and overall survival11. Currently, trastuzumab in combination with 
chemotherapy is considered the standard treatment for patients with HER-2-positive 
advanced GC, and immunohisto chemistry is the primary HER-2 testing method: a 
score of 3+ confirms eligibility for trastuzumab therapy, whereas a 1+ score indicates 
no overexpression. The interpretation of tumours scoring 2+ is open to debate, and 
FISH has been proposed to confirm HER-2 overexpression in such cases7-12. 
EGFR overexpression in primary gastric carcinomas and/or metastases has also been 
reported and is linked to a poor prognosis13–15. An increasing interest has been shown 
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in developing immunohistochemistry-based screening methods to select patients who 
are eligible for treatment with cetuximab, an anti-EGFR monoclonal antibody used in 
advanced colorectal cancer15,16. 
Signal transduction between HER receptors and the nucleus is mediated by a small 
protein encoded by the KRAS gene17. In human oncology, the importance of the 
EGFR/HER-2/KRAS signalling pathway in GC is well established. KRAS mutations 
activate RAS proteins that continuously stimulate the signalling pathways in the 
absence of upstream stimulation of EGFR. Consequently, tumours bearing a KRAS 
mutation are less likely to respond to anti-EGFR drugs17. 
In veterinary medicine, EGFR protein expression has been detected in numerous 
tumour types, including canine mammary tumours, primary brain tumours, nasal 
carcinomas, lung carcinomas and osteosarcomas18–22. HER-2 overexpression is 
reported in 19% to 35% of canine mammary neoplasms 23– 25. In a recent comparison 
study, Singer et al. studied canine EGFR and HER-2 expression and biology using 
mammary cancer cell lines, observing a substantial similarity between human and 
canine EGFR and HER-2 tumour-associated antigens. The antigens were recognised 
by trastuzumab and cetuximab antibodies, leading to growth inhibition in canine 
mammary cancer cell lines. This finding supports the development of novel targeted 
therapies and adjuvant strategies for the treatment of EGFR/ HER-2-expressing 
canine cancers26. Conversely, the EGFR/ HER-2/KRAS pathway has never been 
investigated in canine gastric tumours. 
The aim of the present study was to evaluate EGFR and HER-2 immunohistochemical 
expression and KRAS mutational status in a series of canine gastric tumours. More 
in-depth knowledge of the role of these molecular pathways could provide new 
insights for the treatment of canine gastric tumours and for the evaluation of dogs as a 
comparative model for human cancers. 
 
3. Materials and methods 
 
Ethics Statement 
This study is a retrospective investigation carried out on archived tissue samples from 
dogs with gastric tumours. As the research did not influence any therapeutic decision 
in human subjects, approval by an Ethics Committee was not required. However, all 
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diagnostic and therapeutic procedures were performed in accordance with the “Public 
Health Service Policy on Humane Care and Use of Laboratory Animals”. 
All the examined samples were collected for diagnostic purposes as part of routine 
standard care. Owners gave informed consent to the use of clinical data and stored 
biological samples for teaching and research purposes. 
 
Selection Criteria  
Formalin-fixed and paraffin-embedded (FFPE) tissue samples from dogs with a 
histological diagnosis of benign or malignant epithelial gastric tumours were retrieved 
from the archives of the Department of Veterinary Medical Sciences, University of 
Bologna, Italy, the Veterinary Oncology Center, Sasso Marconi, Italy, and the Faculty 
of Veterinary Medicine, Ghent University, Belgium. Only primary benign and 
malignant epithelial gastric tumours, as confirmed by clinical and/or post-mortem 
findings, were used. Endoscopic biopsies and surgical or post-mortem samples have 
also been included. Reference haematoxylin-eosin stained sections were reviewed by 
an expert veterinary pathologist (GB) to confirm the original diagnosis and to 
standardise the pathological classification according to WHO guidelines for the 
classification of gastrointestinal tumours of domestic animals27. Tumours were 
divided into two main histological groups for statistical purposes: intestinal-type 
(comprising tubular/papillary adenocarcinomas) and diffuse-type (comprising signet 
ring/mucinous carcinomas and anaplastic carcinomas)28. Only tissue sections 
containing more than 50% of tumour cells were included in the study. If available, 
tumour stage according to the tumour node metastasis (TNM) classification proposed 
by the American Joint Committee on Cancer was recorded29. EGFR/ HER-2 
expression was also investigated in 10 samples of normal canine gastric mucosa (from 
the archives of the Department of Veterinary Medical Sciences, University of 
Bologna, Italy). 
 
EGFR and HER-2 Immunohistochemistry 
EGFR and HER-2 expression was detected by immunohistochemistry (IHC) using 
commercial anti-human antibodies whose reactivity in canine tissues has previously 
been validated19–30. Four-micrometer-thick FFPE tissue sections were de-waxed and 
rehydrated. Endogenous peroxidase activity was blocked by incubation for 30 min 
with 3% hydrogen peroxide in distilled water. For EGFR, antigen retrieval was 
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obtained by incubating sections in a 0.05% protease XIV (from Streptomyces griseus, 
P5147-1G, Sigma Aldrich, MO, USA) solution (pH 7.5) for 15 min at 37°C. 
Subsequently, sections were incubated for 60 min at 37°C in a humid chamber with 
the primary antibody (EGFR Ab-10, clone 111.6; mouse monoclonal; NeoMarkers, 
Fremont, CA, USA) diluted 1:100 in phosphate buffered saline (PBS; pH 7.4, 0.01 
M). Sections were incubated with a high sensitivity detection kit (EnVision Plus-
HRP, Dako, Glostrup, Denmark), according to the manufacturer’s instructions. 
For HER-2, antigen was retrieved with citrate buffer (2.1 g citric acid 
monohydrate/litre distilled water), pH 6.0, and heated for two 5-min periods in a 
microwave oven at 750 W. Sections were treated with a protein-blocking solution 
(Protein Block Serum-Free, Dako) for 20 min. Tissue sections were then incubated 
overnight at 4°C with the primary antibody (anti c- erb-B2 oncoprotein; rabbit 
polyclonal, Dako) diluted 1:50 in a solution of 1% bovine serum albumin and PBS. 
Sites of primary antibody binding were identified using a streptavidinbiotin-
peroxidase kit (LSAB, Dako) and diaminobenzidine was used as chromogen (0.04% 
for 10 min at room temperature). 
Sections were then counterstained with Papanicolaou’s hematoxylin. Sections of 
canine mammary carcinomas were used as positive controls, as we know they express 
the tested antigens. Negative controls were obtained by substituting the primary 
antibody with an unrelated serum. 
The immunohistochemical expression of EGFR was graduated as follows: 0, no 
staining observed or membrane staining in <1% neoplastic cells; 1+, weak complete 
or incomplete membrane staining in >1% neoplastic cells; 2+, moderate complete or 
incomplete membrane staining in >1% neoplastic cells; 3+, strong complete or 
incomplete membrane staining in >1% neoplastic cells. Cases with an EGFR score 
≥1+ were considered positive31. HER-2 was evaluated according to the criteria 
proposed by Hofmann et al32 for human GC. HER-2 positivity (3+ IHC reaction) was 
defined as strong, complete or basolateral membranous immunoreactivity in at least 
10% of tumour cells. In biopsies, a cluster (approximately five or more) of positively 
stained cells was considered positive12. EGFR and HER-2 expression was further 
evaluated in biopsy samples of gastric mucosa from ten dogs without gastric tumor. 
 
DNA Extraction and KRAS Gene Analysis 
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FFPE block-derived sections from gastric lesions were reviewed for quality and 
cellular content. DNA was extracted from 5-µmFFPE sections. Cells were lysed in 50 
mM KCl, 10 mM Tris-HCl pH 8.0, 2.5 mM MgCl2 and Tween-20 0.45%, with the 
addition of Proteinase K at a concentration of 1.25 mg/ml, overnight at 56°C. 
Proteinase K was inactivated at 95°C for 10 minutes after which samples were 
centrifuged twice to eliminate debris. Supernatant was assessed for DNA quality and 
quantity by Nanodrop (Celbio, Milan, Italy) and was then submitted to PCR 
amplification. 
Exon 1 of canine KRAS gene was amplified by PCR using the following primers: 
forward 5’-CTGCACTGAATTTTCTGAAGCA-3’ and reverse 5’-
AAAATGGGCCTGCACAAAT’-3’. PCR products were purified using the Minielute 
PCR purification kit (Qiagen, Hilden, Germany) and then submitted to sequencing 
using the BigDye Terminator 3.1 Reaction Cycle Sequencing kit (Applied 
Biosystems, Foster City, CA, USA). Sequence reactions were purified using the 
DyeEx 2.0 Spin kit (Qiagen) and separated by capillary electrophoresis with laser-
induced fluorescence detection (3130 Genetic Analyzer, Applied Biosystems). 
Sequencing products were analysed in comparison with the wild type sequence of the 
gene. 
 
Statistical Analysis 
The association between EGFR/HER-2 expression (positive/negative) and clinical 
pathological parameters (tumour stage, location, malignancy and histotype) were 
tested for significance with Fisher’s exact test. Significance was set at p<0.05. Tests 
were carried out with GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, 
USA). 
 
4. Results  
 
Nineteen samples have been collected (7 endoscopic biopsies, 8 surgical samples and 
4 post-mortem samples). There were five benign tumours (26.3%; 1 tubular adenoma, 
1 papillary adenoma, and 3 tubulopapillary adenomas) and 14 gastric carcinomas 
(73.7%; 1 in situ carcinoma, 2 tubular adenocarcinomas, 1 papillary adenocarcinoma, 
1 tubulopapillary adenocarcinoma, 8 mucinous/signet ring cell carcinomas and 1 
undifferentiated carcinoma). There were 5 intestinal-type (35.7%) and 9 diffuse type 
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carcinomas (64.3%) according to Lauren’s classification28. Tumours were located in 
the cardia (n = 1; 5.9%), gastric fundus (n = 2; 10.5%), lesser curvature (n = 6; 
31.6%) and pyloric antrum (n = 8; 42.1%). In two (10.5%) cases, tumour location was 
unavailable. No statistical association has been found between tumour location and 
histological type. Grossly, diffuse-type tumours most often appeared as a diffuse 
thickening of gastric mucosa (linitis plastica), while intestinal-type tumours 
frequently had the appearance of polypoid-like lesions or mucosal plaques with 
ulceration. Among malignant tumours, 3 were stage 0, 4 were stage I, 2 were stage III 
and 4 were stage IV. In one case the staging was unavailable. The mean age of the 
affected dogs was 10.8 years for adenomas and 8.8 for carcinomas (range 3–16 
years); 12 dogs were males (63.2%) and 7 were females (36.8%). There were 3 
Boxers, 2 Shih-tzus, 5 crossbreeds, and 9 dogs of other breeds. Animal details are 
summarised in Table 1. 
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Table 1. Breed, age, sex, tumor location, type of sample, histological diagnosis, 
tumour node metastasis (TNM) stage, EGFR and HER-2 and KRAS gene analysis of 
the animals. 
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EGFR and HER-2 Expression 
The EGFR protein was expressed in 8 (42.1%) out of 19 samples. Five (26.3%) cases 
were scored as 1+, 1 (5.3%) case was scored as 2+ and 2 (15.8%) cases were scored 
as 3+ (Figure 1a,b). No differences were observed in EGFR expression on the basis of 
tumour stage, location or malignancy. The percentage of EGFR-positive lesions was 
significantly higher among intestinal-type (80%) than diffuse-type (11.1%, p = 0.023) 
tumors (Table 2). Eleven (57.9%) tumours were considered HER-2 positive (3+). In 
the remaining cases (n = 7; 36.9%), HER-2 expression was classified as 2+ (Figure 
1c,d). In one dog (case 19), HER-2 analysis was not possible because of tissue 
exhaustion. No statistically significant differences in HER-2 positivity were observed 
on the basis of clinical pathological parameters (Table 2). In adenomas, HER-2 
staining was more intense in dysplastic areas. 
 
Parameter 
EGFR ≥1+         
(n= 8) 
 
P 
HER-2 3+          
(n= 11) 
 
P 
Sex  ns  ns 
    Male 4/12  6/11  
    Female 4/7  5/7  
Age, years  ns  ns 
    < 10 years 2/9  3/9  
    > 10 years 6/10  8/9  
Localisation  ns  ns 
    Pyloric antrum 4/8  6/11  
Malignancy  ns  ns 
    Adenomas 3/5  3/5  
    Carcinomas 5/14  8/13  
Histotype  0.023  ns 
    Intestinal type 4/5  4/5  
    Diffuse type 1/9  4/8  
Stage IV  ns  ns 
    Yes 3/4  4/4  
    No 2/9  3/9  
Table 2. Association between EGFR/HER-2 status and clinic-pathological parameters 
in 19 canine gastric epithelial neoplasms. 
 
EGFR/HER-2 expression was not detected in the 10 samples of normal gastric 
mucosa, with the exception of scattered foci of weak basolateral positivity (Figure 
1e,f). 
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Fig 1. EGFR and HER-2 immunohistochemistry of canine samples. (A). Dog, 
stomach. Signet ring cell carcinoma (case No. 15). EGFR immunohistochemistry. 
Faint and partial membrane labelling of the neoplastic cells (1+). Haematoxylin 
counterstain. 200x. (B) Dog, stomach. Papillary adenoma (case No. 2). EGFR 
immunohistochemistry. Strong and complete membrane labeling of the neoplastic 
cells (3+). Haematoxylin counterstain. 100x. (C) Dog, stomach. Tubulopapillary 
adenoma (case No. 5). HER-2 immunohistochemistry. Moderate basolateral 
membrane labeling of the neoplastic cells (2+). Haematoxylin counterstain. 200x. (D) 
Dog, stomach. In situ tubulopapillary carcinoma (case No. 6). HER-2 
immunohistochemistry. Strong and complete membrane labeling of the neoplastic 
cells (3+). Haematoxylin counterstain. 200x. (E) Dog, stomach, fundus. EGFR 
immunohistocheistry. Negative labeling of the mucosal epithelium. Faint granular 
cytoplasmic positivity of the parietal cells. Haematoxylin counterstain. 200x. (F) Dog, 
stomach, pyloric antrum. HER-2 immunohistochemistry. Scattered foci of faint 
basolateral positivity. Haematoxylin counterstain. 200x. 
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KRAS Gene Analysis 
All five adenomas showed a wild type KRAS gene status. Of the 14 carcinomas, 13 
were KRAS wild type and one was mutated. The identified mutation was a G to C 
transversion at the first position of codon 12 of the gene (GGT è CGT (G12R)) (Also 
know as NC_006609.03:c.36G>C following HGVS nomenclature33) which induces 
the substitution of a glycine with an arginine. The mutation was found in stage IV 
mucinous/signet-ring cell carcinoma (Figure 2). 
 
 
 
Fig 2. KRAS analysis. Mutation analysis performed by direct sequencing on wild 
type (A) and mutated (B) samples. Arrows indicate the point mutation. 
 
5. Discussion 
 
HER-2 and EGFR are transmembrane tyrosine kinases that can promote tumour 
genesis and progression. Expression of HER-2 and EGFR appear to be closely 
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related, and one or both proteins are frequently overexpressed in gastric epithelial 
cancer cells8. In recent years, new developments in cancer biology have led to the 
emergence of novel molecular-targeted therapeutics. These drugs act selectively on 
cancer cells at a molecular, biochemical and genetic level, specifically targeting 
abnormal cells, with minimal effects on the function of normal cells8. As in humans, 
the prognosis of canine gastric cancer is very poor and currently available therapeutic 
aids fail to significantly prolong survival. The need for new treatment options thus 
encourages in-depth studies on the role of these molecules as potential therapeutic 
targets in veterinary medicine as well. Additionally, strong similarities have been 
observed between human and canine gastric tumour with regard to clinical 
presentation and histopathological features, which indicates the dog as a potential 
comparative model for human GC. 
Our retrospective study was conducted on 19 cases of canine gastric epithelial 
tumours, the small number of cases possibly constituting a limitation. Data on clinical 
stage were not available in six dogs (nos. 1, 2, 3, 4, 5 and 19). A 1.7:1 male to female 
ratio was observed, confirming the male predisposition previously reported by other 
authors2–5. Additionally, our data support the preferential localisation of these 
tumours to the pyloric antrum and lesser curvature34–36. 
Overall, both receptors were expressed in a high percentage of cases (EGFR: 42%, 
HER-2: 61%). All HER-2 negative cases were also negative for EGFR expression 
exept one (case 5), whereas a subset of EGFR negative tumours was found among 
HER-2 positive tumours. Immunohistochemical expression was membranous, 
complete or basolateral. EGFR positivity among tumors was extremely 
heterogeneous, therefore we did not observe major intra-tumour differences in HER-2 
expression. 
In humans, HER-2 immunohistochemical expression varies according to tumour 
location, with a higher rate of HER-2 positivity in GEJ tumours compared to those 
located in the gastric body (34% vs 20%)11. The single most important factor for the 
development of these tumours is the mucosal irritation caused by chronic GE reflux. 
In such case, squamous epithelium is eroded and replaced by columnar epithelium, 
either by intestinal metaplasia or by the extension of columnar epithelium from the 
stomach (Barrett’s oesophagus)36,37. 
HER-2 expression in humans also differs significantly on the basis of histological 
subtype. Intestinal-type cancers usually exhibit higher rates of HER-2 positivity 
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compared to diffuse-type tumors (34% vs 6%)9. No clear correlation has been found 
between EGFR expression and tumour location or histotype. 
Among the cases in this study, only one tumour was located in the GEJ (HER-2, 2+); 
the remaining lesions were almost equally distributed between the gastric fundus and 
the pyloric antrum, with no significant difference in receptor expression. Conversely, 
a higher percentage of intestinal-type compared to diffuse-type carcinomas were 
positive for both markers. However, this difference was only statistically significant 
for EGFR. 
In human GC, HER-2 is involved in the development of relatively early-stage 
carcinogenesis12. Additionally, although the majority of studies conducted in human 
medicine links the overexpression of HER-2 to adverse prognosis12, a small number 
of these studies has not found any correlation with the biological behaviour of the 
tumour38. Likewise, EGFR expression has been associated with increased tumour 
aggressiveness15. Given the retrospective nature of this study, it was not possible to 
trace the clinical follow-up of the majority of cases. Nevertheless, some indication 
about tumour biological behaviour can be inferred from IHC expression in gastric 
mucosa samples from controls compared to those from adenomas and carcinomas. 
Neither receptor was expressed in non-neoplastic gastric mucosa, showing their 
possible involvement in carcinogenesis. Additionally, in benign tumours, HER-2 was 
more intensely expressed in the focal areas of dysplasia, suggesting its potential 
relevance in premalignant lesions. However, as no appreciable differences in marker 
expression has been observed between adenomas and carcinomas and between locally 
advanced and metastatic cancer, a correlation with tumour biological behaviour would 
seem unlikely. 
In human oncology, it has been observed that the KRAS gene is affected by a limited 
number of mutations, more than 90% involving codons 12, 13 and 61 (less relevant). 
These mutations are associated with the constitutive activation of the gene and are 
considered responsible for resistance to treatment with anti-EGFR monoclonal 
antibodies39. 
In gastric carcinomas, the reported frequency of KRAS point mutations is between 8% 
and 10%40,41. Although KRAS mutations represent a prognostic factor for colorectal 
and lung cancer, their correlation with the biological behaviour of gastric tumours is 
still poorly defined39–41. 
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The nucleotide sequence of the canine KRAS gene is close to identical to the human 
one, and the resulting amino acidic sequence is identical42. Kraegel and coworkers 
analysed KRAS activation in a subset of canine non-small cell lung cancers: despite 
the wide disparity in the incidence of non-small cell lung cancer between dogs and 
humans, the frequency of KRAS point mutation was similar. Although species-
specific factors may be responsible for mutations, exposure to common environmental 
carcinogens may account for some of the identified similarities in KRAS activation42. 
Mutation analysis of KRAS performed on our samples showed the presence of a single 
mutation at codon 12. This mutation is among the most frequently detected in humans 
and results in the substitution of a glycine (the only amino acid without a side-chain) 
by an amino acid with a side-chain (arginine), thus leading to a geometric alteration of 
the protein. This results in a lack of GTP hydrolysis which keeps KRAS in a 
permanently activated state43. The mutation was found in a mucinous carcinoma of 
the gastric fundus characterised by a massive infiltration of adjacent structures and 
regional lymph node metastases. Unfortunately, no information was available on the 
clinical course of the case, a 10- year-old male boxer. The potential presence of KRAS 
mutation in dogs should be taken into account when considering to use of targeted 
drugs against the HER pathway as it could represent a mechanism of resistance44. 
In conclusion, the present study revealed a high expression of EGFR and HER-2 in 
canine gastric epithelial tumours, which suggests a role of these receptors in 
carcinogenesis, especially when compared to the constant negativity of normal gastric 
mucosa. Additionally, there was a significantly higher percentage of EGFR positive 
cases among intestinal-type carcinomas. Unlike humans, however, we did not observe 
a relationship between marker expression and anatomical location or the biological 
behaviour of tumours. Finally, a codon 12 mutation in the KRAS gene was identified, 
equivalent to those found in human gastric carcinomas, suggesting that this altered 
pathway may also exert a role in the pathogenesis of gastric cancer in dogs. 
The potential relevance of these molecules as prognostic and predictive markers 
indicates the need for further studies on larger case series involving the use, in 
parallel, of in situ hybridisation and immunohistochemistry. 
In conclusion, the pathological and behavioural similarities between many 
spontaneous canine and human tumours make logical to extend investigations into 
molecular oncogenesis to dogs. Therapeutic targeting of EGFR and HER-2 could be a 
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promising line of research in canine gastric tumour. Further studies are needed to 
evaluate the role of the dog as a model for human GC. 
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CHAPTER IV 
 
IS SERUM TOTAL LDH EVALUATION ABLE TO 
DIFFERENTIATE BETWEEN ALIMENTARY LYMPHOMA AND 
INFLAMMATORY BOWEL DISEASE IN A REAL WORLD 
CLINICAL SETTING? 
 
 
 
 
 
 
Adapted from:  
Terragni R, Morselli-Labate AM, Vignoli M, Bottero E, Brunetti B, Saunders JH. Is 
Serum Total LDH Evaluation Able to Differentiate between Alimentary Lymphoma 
and Inflammatory Bowel Disease in a Real World Clinical Setting? PLoS One. 2016 
Mar 17;11(3):e0151641.doi: 10.1371/journal.pone.0151641 
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1. Abstract  
 
An increase in enzyme lactate dehydrogenase (LDH) in serum is a negative 
prognostic factor for survival in cats affected by lymphoma. Measuring LDH at the 
time of diagnosis has been studied for differentiating neoplastic disease from non-
neoplastic disease in dogs. Inflammatory bowel disease (IBD) and alimentary 
lymphoma (AL) are common diseases in cats. 
The aim of this study was to determine whether elevation of total LDH occurred in 
cats with AL and non-neoplastic gastrointestinal (GI) disease, such as IBD, and to 
evaluate whether this enzyme is useful in supporting the differential diagnosis of 
these specific diseases. 
A retrospective controlled multicenter study was carried-out in a real world setting of 
three Italian private veterinary clinics. Fifty-seven client-owned cats with a history of 
chronic GI symptoms were enrolled; 25 cats were histologically diagnosed as having 
AL and 32 cats as having IBD. Serum samples of total LDH analysis have been 
measured. 
Serum total LDH were significantly higher (P=0.017) in cats with AL (median: 300 
U/L; IQR: 172-351 U/L) than in cats with IBD (median: 191 U/L; IQR: 135-239 
U/L). In particular, serum total LDH values were significantly different between cats 
with AL and those with IBD in neutred males (P = 0.001) while in younger cats (up to 
7 years) the difference was close to the significant level (P = 0.088). A significant 
diagnostic accuracy was found in the overall population (68.6%; P=0.017) with a best 
cut-off value of serum total LDH ranging from 239 to 243 U/L. As far as the accuracy 
in subgroups of cats is concerned, serum total LDH showed good capability of 
differentiating these two conditions in neutered males (P=0.002) (AUC: 0.889; 
sensitivity: 88.9%; specificity: 84.6%; PPV: 80.0%; NPV: 91.7%). 
Although our study showed that gender and age are important factors in 
differentiating serum total LDH between cats with AL and those with IBD, this test 
presents a fair diagnostic accuracy in differentiating between these two conditions in 
the overall population. 
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2. Introduction		
 
Lactate dehydrogenase (LDH) is an enzyme which catalyzes the last step of the 
conversion of pyruvate to lactate during anaerobic glycolysis. Lactate dehydrogenase 
is found in the cells of almost all body tissues. There are five isoenzymes with LDH 
activity. Different normal human tissues contain different patterns of these five 
isoenzymes1. Alteration in LDH isoenzymes levels has been observed during 
development, under changing biological conditions and in response to pathological 
processes. Lactate dehydrogenase activity in serum increases as a marker of cellular 
necrosis2. 
Serum LDH and its isoenzyme distribution have been studied extensively in various 
body cancers. Malignant tumor tissue or contiguous tissue damaged by a tumor 
liberates enzymes into circulation which contribute towards an abnormal increase in 
enzyme levels3. Regardless of tissue origin, studies on LDH distribution in different 
types of malignant tumors have shown LDH to be abnormally increased3. Moreover, 
LDH has also been identified as a valuable predictive and/or prognostic biomarker for 
different types of carcinoma4. Serum LDH is commonly increased in patients with 
hematopoietic malignancies, such as Hodgkin’s lymphoma, non-Hodgkin’s 
lymphoma or multiple myeloma5. Lactate dehydrogenase is one of the risk factors 
included in the International Prognostic Index, and it is considered to be a strong 
predictor of survival in patients with aggressive lymphoid cancers6. The total LDH 
level in the blood may be a meaningful diagnostic parameter in human cancer 
patients, but the clinical significance of serum isoenzymatic patterns of LDH is still 
under discussion; the LDH-5 isoform has been added to the list of highly promising 
targets for cancer treatment5. 
In veterinary medicine, LDH has been evaluated in dogs, and it has been 
demonstrated that LDH levels have limited use in differentiating dogs with cancer 
from both healthy dogs and dogs with non-neoplastic diseases, as well as in 
differentiating among different types of tumors7. On the other hand, the determination 
of LDH activity may help in identifying episodes of recurrence in dogs with 
lymphoma8. In feline oncology, it has been reported that an increase in serum LDH 
activity in the initial chemistry profile was a negative prognostic indicator for survival 
in cats with lymphoma9. As far as isoenzymes are concerned, it has been reported that 
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LDH-5 has a dominant concentration and LDH-1 is very scant in normal feline 
leukocytes, thus suggesting that the leukocytes of cats tend to produce more energy 
under anaerobic conditions compared to the leukocytes of dogs or rabbits10. 
Lymphomas are a common malignancy affecting cats11, representing 30% of feline 
tumors12. Alimentary lymphoma is the most common form of lymphoma in cats13. A 
majority of the T-cell immunophenotype (83%) in feline GI lymphoma suggests that 
previous studies may have underestimated lymphoma incidence, due to the difficulty 
in distinguishing mucosal T-cell lymphoma from lymphoplasmacytic IBD12. The 
clinical presentation of feline AL is quite similar to feline IBD14, a chronic 
enteropathy characterized by persistent or recurrent GI symptoms and histologically 
confirmed inflammation15. 
The aims of this study were: 1) to determine whether elevation of total LDH occurred 
in cats with AL and non-neoplastic GI diseases, such as IBD, and 2) to evaluate 
whether this enzyme is useful in supporting the differential diagnosis of these specific 
diseases. 
 
3. Materials and methods 
 
Experimental Design 
All consecutive client-owned cats with a history of chronic GI symptoms, such as 
weight loss, anorexia, vomiting, and small bowel diarrhea, referred to three Italian 
private veterinary clinics (“Giardini Margherita” Veterinary Clinic, Bologna; 
“Modena Sud” Veterinary Clinic, Spilamberto, Modena; ”Argentina” Polyclinic, 
Arma di Taggia, Imperia) were selected for a prospective controlled multicenter study 
carried out between January 2013 and September 2015. 
The serum LDH levels were compared between AL and IBD cats, and the diagnostic 
accuracy in differentiating between these two diseases was evaluated. The possible 
effect of gender and age was also taken into account. 
All owners gave their oral informed consent for the enrollment of their cats into the 
study. All animals received humane care according to the criteria outlined in the 
"Guide for the Care and Use of Laboratory Animals (1996)" prepared by the National 
Academy of Sciences. Ethical approval was not required since no animal research was 
involved in the study and the data were collected from the records of cats managed 
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according to the usual clinical practice in a real world setting of three veterinary 
centers. 
 
Selection Criteria 
All cats underwent a physical examination, fecal flotation assays, fecal enzyme-linked 
immunosorbent assay (ELISA) immunoassay for Giardia, a complete blood count, a 
biochemistry profile, urinalysis, FIV-FeLV serologic ELISA test and serum total T4. 
Abdominal ultrasonography was performed in all patients to exclude non-
gastrointestinal causes for their clinical symptoms and to study the GI features. 
 
Exclusion Criteria 
Cats which responded to treatment for Giardiasis (fenbendazole 50 mg/kg per os once 
a day for 5 days) or to specific diets (hydrolyzed protein diet, etc.) were excluded in 
order to exclude adverse food reaction. Patients with primary renal, hepatic or 
pancreatic disease, hyperthyroidism, diabetes, toxic causes or other intestinal parasitic 
diseases as well as patients which palpable abdominal lesion or lymphadenopathy 
appreciable on palpation were also excluded from the study. 
 
Diagnostic Procedures 
All the cats underwent abdominal ultrasonographic (US) examination and endoscopic 
GI biopsy to collect stomach and duodenum histological samples in order to 
differentiate between the AL and the IBD groups. Endoscopies were performed by 
two endoscopists (R.T. and E.B.). Ileoscopy and ileum biopsy were not routinely 
performed in the centers involved in the study. A histopathological diagnosis of all 
bioptic samples was carried out according to the histopathological standards of GI 
inflammation of endoscopic bioptic samples published by the World Small Animal 
Veterinary Association (WSAVA) Gastrointestinal Standardization group16,17. The 
IBD cases were classified as mild, moderate and severe18. Cases of lymphomas were 
graded applying the modified World Health Organization (WHO) classification for 
lymphoma19,20 according to the following method. Lymphomas with 0 to 5 
mitoses/400x field were classified as low grade, those with 6 to 10 mitoses/400x field 
were classified as medium grade and those with greater than 10 mitoses/400x field 
were classified as high grade14. Immunohistochemistry was required if it was needed 
to confirm the presence of GI lymphoma. 
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Immunohistochemistry 
Two sections 4 µm-thick were cut from the paraffin blocks and labeled by 
immunohistochemistry with antibodies anti-CD3 (clone CD3-12, Leukocyte Antigen 
Biology Laboratory, UC Davis School of Veterinary Medicine, Davis, CA, USA) and 
anti-CD79 (clone HM57, Santa Cruz Biotechnology, Inc., Dallas, TX, USA). The 
sections were dewaxed in toluene and rehydrated. Endogenous peroxidase was 
blocked by immersion in H2O2 0.3% in methanol for 30 min. The sections were then 
rinsed in Tris buffer, and the antigen was retrieved with citrate buffer (pH 6.0, CD3 
sections) and with ethylenedinitrilotetraacetic acid (EDTA) buffer (pH 8.0, CD79 
sections) by heating for two 5-min periods in a microwave at 750 W, followed by 
cooling at room temperature for 20 min. The antibodies CD3 and CD79 were diluted 
in phosphate buffered saline (PBS) 1:20 and 1:750, respectively. All antibodies were 
incubated with the tissue sections overnight at 4°C. Binding sites were revealed using 
a secondary biotinylated antibody (dilution 1:200) and amplified using a commercial 
avidin-biotinperoxidase kit (VECTASTAIN ABC Kits, Vector Laboratories, Ltd., 
Peterborough, UK). Chromogen DAB (3,30diaminobenzidine; 0.05% for 3 minutes at 
room temperature) was used. The slides were counterstained with Papanicolaou 
hematoxylin. The primary antibody was replaced with an irrelevant, isotype-matched 
antibody as a negative control. Reactive lymph nodes were used to assess the 
specificity of the immunohistochemical procedure. 
 
LDH Evaluation 
The serum total LDH was evaluated at the time of clinical presentation after 12 hours 
of fasting in all cats. Blood was taken from the jugular vein and the serum was 
obtained by centrifugation after 20 minutes. 
A photometric method for assessing total LDH was carried out in one laboratory 
(Olympus analyzer; IDEXX Laboratories S.r.l., Milan, Italy; reference range: 0–182 
U/L; intra- and inter- assay coefficients of variation (CVs): unavailable) while a 
kinetic optimized method (SCE, LDH-P; BT1500 VET; Futurlab S.r.l., Limena, PD, 
Italy; reference range: 63–273 U/L; intra- and inter-assay CVs: 1.69–3.86% and 1.26–
2.13%, respecively) was used in the other two laboratories. 
The values detected by means of the photometric method were proportionally 
adjusted to the upper reference limit of the kinetic optimized method (273 U/L). 
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Statistics 
Median, interquartile range (IQR), range and frequencies were reported as descriptive 
statistics. Age and weight were described as scale variables and were also 
dichotomized for analysis: a cut-off value of 7 years was chosen for age21,22,23 while 
weight was dichotomized according to the median value (4 kg). 
The Fisher’s exact, the Pearson’s chi-square and the linear-by-linear chi-square tests 
were applied to analyze the dichotomous, nominal and ordinal discrete variables, 
respectively, while the Kruskal-Wallis test, the Wilcoxon/Mann-Whitney rank test 
and the Spearman rank correlation were used for analyzing scalar variables. 
The diagnostic accuracy of serum total LDH values in differentiating AL from IBD 
cats was evaluated by means of the area (AUC) under the receiver operating 
characteristics (ROC) curve. The standard error (SE) of the AUC was computed by 
means of a distribution- free non-parametric method while the best cut-off value of 
serum total LDH was identified by means of a maximum likelihood ratio (LR) 
method according to the following formula: LR = (Frequency of true positive + 
Frequency of true negative) / (Frequency of false positive + Frequency of false 
negative)24. Sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) were evaluated using the best cut-off value. 
Data were managed and analyzed by means of the IBM SPSS Statistics package 
(version 23.0; IBM Co., Armonk, NY, USA) and a two-tailed P value equal to 0.05 
was chosen as the limit of statistical significance. 
 
4. Results  
 
Patients 
Fifty-seven client-owned cats were used: 52 European shorthair cats, 1 Birman cat, 2 
Maine coons, 1 Norwegian forest cat and 1 Persian. Twenty-two (38.6%) were 
neutered males and 35 (61.4%) were spayed females; median age was 10 (IQR: 7.5-
12) years, range: 1–16 years (n = 43, 75.4% were over 7 years of age) and the median 
weight was 4.0 (IQR: 3.0-4.5), range: 2–10 kg (n = 31, 54.4% weighed more than 4 
kg). Abnormalities detected on physical examination included poor body condition 
(body condition score, BSC: 1-2/5) (n = 25; 43.9%), poor coat condition (n = 26; 
45.6%), lethargy (n = 11; 19.3%), diffusely thickened intestinal loops (n = 16; 
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28.1%), and gaseous or liquid intestinal matter (n = 16; 28.1%). Fecal flotation assays 
and fecal ELISA immunoassays for the detection of Giardia were negative in all 
cases. 
Clinicopathological abnormalities included mild anemia (n = 17; 29.8%), mild 
neutrophilia (n = 15; 26.3%) and mild hypoalbuminemia (n = 6; 10.5%) as well as 
mild elevations of azotemia (n = 9; 15.8%), bilirubin (n = 8; 14.0%) and liver 
enzymes (n = 5; 8.8%). All the cats had a negative serologic ELISA test for retrovirus 
except for one which was FeLV positive (1.8%). Serological T4 was normal in all 
cats. 
 
Study Groups 
Twenty-five cats had a diagnosis of AL (43.9%) and 32 cats a diagnosis of IBD 
(56.1%). Of the 25 AL cats, 16 were low grade (64.0%) and 9 were high grade 
(36.0%) (no cats with intermediate grade were diagnosed). The lymphoma was 
located in the stomach in 17 out of 25 cats (68.0%), in the small bowel in 7 cats 
(28.0%) and in both organs in 1 cats (4.0%). Immunophenotyping on histological 
samples was available in 24 AL cats (96.0%); T-lymphoma was present in 15 of these 
cats (62.5%) and B-lymphoma was present in 9 cats (37.5%). 
Of the 32 IBD cats, 6 (18.8%) had mild disease, 14 had moderate disease (43.8%) and 
12 cats had severe disease (37.5%). 
Ultrasonographic examination revealed moderate to severe GI wall thickening 
together with loss of layering in the 9 cats with high grade lymphoma (100%), mild 
increased wall thickening (muscular layer) with normal layering in 22 cases (11 cases 
in the 16 cats with low grade lymphoma, 68.7%; 11 cases in cats with IBD, 34.4%), 
and normal wall thickening and normal layering in 26 cats (5 cases in the 16 cats with 
low grade lymphoma, 31.3%; 21cases in cats with IBD, 65.6%). Mild to moderate 
mesenteric lymph node enlargement was also visible in 25 cats, 18 with lymphoma 
(72.0%) and 7 with IBD (21.9%) (Table 1). 
The upper GI endoscopy of the 9 cats with high-grade lymphoma showed an 
abnormal appearance of the gastric mucosa in 8 cases (88.9%); there was decreased 
distensibility of the gastric body also after insufflation, mild to moderate hyperemia, 
increased granularity and friability) and focal or linear erosion or ulcers in 4 cases 
(44.4%). No relevant alterations of the gastric mucosa were found in low-grade 
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lymphoma and IBD cats. In the small bowel of all the cats, the mucosa was friable 
and irregular, with increased graininess and coerced villi (Table 1). 
 
Table 1. Ultrasonographic (US) and endoscopic (EDS) findings. 
 Total AL Low 
grade 
AL High 
grade 
IBD 
 57 16 9 32 
US Wall thickening     - Mod/Sev	 9 0 9 (100%) 0 
- Mild	 22 11 (68.7%) 0 11 (34.4%) 
- Normal	 26 5 (31.3%) 0 21 (65.6%) 
US Node enlargement 25 18/25 (72.0%) 7 (21.9%) 
EDS GI abnomality         8 0 8 (88.9%) 0 
EDS GI erosions 4 0 4 (44.4%) 0 
 
 
The characteristics of the two study groups are shown in Table 2. Breed, gender and 
body weight were not significantly different between the two groups while the AL 
cats were older than the IBD cats: in fact, the majority of them were over 7 years of 
age (n = 23/25, 92.0% vs. n = 20/32, 62.5%; P = 0.013). 
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Table 2. Characteristics of the two study groups. 
 All cases 
 
(n=57) 
Alimentary lymphoma 
(n=25) 
IBD 
 
(n=32) 
P value 
Severity of the disease: 
 
- 16 (64.0%) Low grade 
9 (36.0%) High grade 
6 (18.8%) Mild 
14 (43.8%) Moderate 
12 (37.5%) Severe 
- 
Breed:  
- European shorthair 
- Others 
 
52 (91.2%) 
5 (8.8%) 
 
25 (100%) 
0 
 
27 (84.4%) 
5 (15.6%) 
P=0.061 a 
Gender: 
- Neutered males 
- Spayed females 
 
22 (38.6%) 
35 (61.4%) 
 
9 (36.0%) 
16 (64.0%) 
 
13 (40.6%) 
19 (59.4%) 
P=0.788 a 
Age (years): 
- Median (IQR) 
- >7 years 
 
10.0 (7.5-12.0) 
43 (75.4%) 
 
10.0 (9.0-12.0) 
23 (92.0%) 
 
9.0 (5.5-11.8) 
20 (62.5%) 
 
P=0.118 b 
P=0.013 a 
Weight (kg): 
- Median (IQR)  
- 4 kg or more 
 
4.0 (3.0-4.5) 
31 (54.4%) 
 
4.0 (3.3-4.5) 
13 (52.0%) 
 
4.0 (3.0-4.4) 
18 (56.3%) 
 
P=0.758 b 
P=0.794 a 
a Fisher’s exact test 
b Wilcoxon/Mann-Whitney rank test for independent samples 
 
Distribution of LDH in AL and IBD Cats 
The distribution of the serum total LDH values observed in AL and IBD cats is shown 
in Fig 1; the descriptive statistics, stratified according to the characteristics of AL and 
IBD cats, are reported in Table 3. Median standardized serum total LDH values were 
higher in cats with lymphoma than in those with IBD: 300 (QR: 172-351) in AL vs. 
191 (IQR:135-239) in IBD. The comparison between AL and IBD cats was 
statistically significant (P = 0.017), as well as a significantly (P = 0.002) higher 
frequency of cats with serum total LDH values higher than the upper reference limit 
was found in AL cats (n = 16, 64.0%) than in IBD cats (n = 7, 21.9%). 
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Fig 1. Distribution of serum total LDH values in alimentary lymphoma and IBD cats. 
Data are reported as U/L adjusted to the upper reference limit of the kinetic optimized 
method method (273 U/L). 
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Table 3. Descriptive statistics of serum total LDH values (U/L) according to the 
characteristics of alimentary lymphoma and IBD. 
 
 Descriptive statistics  Abnormal values 
Median (IQR) Range    
Alimentary lymphoma (n=25) 300 (172-351) 29-800   16 (64.0%) 
Location: 
- Stomach (n=17) 
- Small bowel (n=7) 
- Stomach and small bowel (n=1) 
 
302 (164-351) 
291 (168-640) 
203 (-) 
 
29-465 
114-800 
- 
   
11 (64.7%) 
4 (57.1%) 
1 (100%) 
 P=0.990 a   P=0.702 b 
Immunophenotype: 
- T-lymphoma (n=15) 
- B-lymphoma (n=9) 
 
291 (131-302) 
374 (296-368) 
 
29-800 
152-465 
   
8 (53.3%) 
8 (88.9%) 
 P=0.096 c   P=0.178 d 
Grade: 
- Low grade (n=16) 
- High grade (n=9) 
 
267 (140-301) 
347 (296-368) 
 
29-800 
152-465 
   
8 (50.0%) 
8 (88.9%) 
 P=0.074 c   P=0.088 d 
IBD (n=32): 
Grade: 
- Mild (n=6) 
- Moderate (n=14) 
- Severe (n=12) 
191 (135-239) 
 
158 (116-246) 
179 (130-238) 
203 (140-387) 
95-786 
 
103-289 
95-786 
98-454 
  7 (21.9%) 
 
1 (16.7%) 
2 (14.3%) 
4 (33.3%) 
 P=0.309 f   P=0.328 e 
a Kruskal-Wallis test 
b Pearson chi-square 
c Wilcoxon/Mann-Whitney rank test for independent samples 
d Fisher’s exact test 
e Liner-by-linear chi-square 
f Spearman rank correlation 
 
 
Although no significant relationships were found between serum total LDH values 
and the characteristics of both AL and IBD cats (Table 3), higher median total LDH 
values were found in cats with high grade AL (347 U/L, IQR: 296-368 U/L vs. 267 
U/L, IQR: 140-301 U/L in low grade; P = 0.074) and in those with B-lymphoma (374 
U/L, IQR: 296-368 U/L vs. 291 U/L, IQR: 131-302  U/Lin T-lymphoma; P = 0.096) 
as well as a non significant higher frequency of abnormal LDH values was found in 
cats with severe IBD (33.3% vs. 16.7% and 14.3% in mild and moderate IBD, 
respectively; P = 0.328). 
Table 4 shows the detailed results of the analyses carried out within the various 
classes of gender and age. In AL cats, the spayed females (P = 0.037) had 
significantly lower serum total LDH values than neutered males, while no significant 
Chapter	IV	Total	serum	LDH	evaluation	
75	
differences were found for gender in IBD cats (P = 0.472). On the other hand, serum 
total LDH values were significantly higher in older than in younger IBD cats (P = 
0.048). In addition, significantly higher values of LDH in AL versus IBD cats were 
found in neutered males (P = 0.001) while in cats up to 7 years of age the difference 
was only close to the significant level (P = 0.088). 
 
Table 4. Comparison of serum total LDH values (U/L) between alimentary 
lymphoma and IBD cats. Data are shown as median values and interquartile ranges 
(IQRs).  
 
Tested factors Alimentary lymphoma 
(n=25) 
IBD 
(n=32) 
P value 
Gender (All cases): 
- Neutered males 
- Spayed females 
P value 
 
353 (289-525) 
267 (136-326) 
0.037 
 
156 (125-224) 
191 (139-285) 
0.472 
 
0.001 
0.523 
- 
Age (All cases): 
- Up to 7 years 
- Over 7 years 
P value 
 
351 (350-ND) 
293 (168-347) 
0.240 
 
137 (118-207) 
203 (159-274) 
0.048 
 
0.088 
0.165 
- 
ND: not detectable 
 
 
Diagnostic Accuracy 
The ROC analysis showed a significant overall diagnostic accuracy (AUC±SE = 
0.686±0.075; P = 0.017; Fig 2). The maximum LR value (2.71) identified the best cut-
off as ranging from 239 to 243 U/L with a sensitivity, specificity, PPV and NPV: 
68.0% (17/25), 78.1% (25/32), 70.8% (17/24) and 75.8% (25/33), respectively. 
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Fig 2. Receiver operating characteristics (ROC) curve of serum total LDH values in 
differentiating AL from IBD cats. The best cut-off (corresponding to a serum total 
LDH value ranging 239-243 U/L with a LR value equal to 2.71) is identified in the 
ROC curve.  
 
 
Fig 3 and Table 5 show the results of the ROC analysis stratified according to the 
characteristics of the cats studied. Gender (P = 0.010) and age (P = 0.014) 
significantly conditioned the diagnostic accuracy; in fact, significant values of 
accuracy were only found in neutered males (88.9%; P = 0.002) while in cats up to 7 
years of age it was only close to the significant level (91.7%; P = 0.068). In particular, 
sensitivity prevailed both in neutered males (88.9%) and in younger cats (100%); 
these figures provided good values of NPV in both groups (91.7% in neutered males 
and 100% in cats up to 7 years of age).  
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Fig 3. Receiver operating characteristics (ROC) curves of serum total LDH values in 
differentiating AL from IBD cats stratified according to gender (a) and age (b). The 
best cut-off values are also identified in the ROC curves.  
 
            
              
 
a 
b 
Chapter	IV	Total	serum	LDH	evaluation	
78	
 
Table 5. Results of the ROC analysis of serum total LDH values in differentiating AL 
from IBD cats stratified according to gender and age. 
 
Factors tested  Accuracy 
(AUC±SE) 
Max LR Best 
cut-off 
Sensitivity Specificity PPV NPV 
Gender: 
- Neutered males 
 
 
- Spayed females 
 
0.889±0.074 
(P=0.002) 
 
0.566±0.102 
(P=0.508) 
 
P=0.010 
 
6.55 
 
 
1.85 
 
 
- 
 
231-285 
 
 
239-243 
 
 
- 
 
8/9 
(88.9%) 
 
9/16 
(56.3%) 
 
- 
 
11/13 
(84.6%) 
 
14/19 
(73.7%) 
 
- 
 
8/10 
(80.0%) 
 
9/14 
(64.3%) 
 
- 
 
11/12 
(91.7%) 
 
14/21 
(66.7%) 
 
- 
Age: 
- Up to 7 years 
 
 
- Over 7 years 
 
0.917±0.080 
(P=0.068) 
 
0.624±0.089 
(P=0.165) 
 
P=0.014 
 
23.0 
 
 
2.35 
 
 
- 
 
289-349 
 
 
239-243 
 
 
- 
 
2/2 
(100%) 
 
15/23 
(65.2%) 
 
- 
 
11/12 
(91.7%) 
 
15/20 
(75.0%) 
 
- 
 
2/3 
(66.7%) 
 
15/20 
(75.0%) 
 
- 
 
11/14 
(100%) 
 
15/23 
(65.2%) 
 
- 
AUC: area under the curve; LR: likelihood ratio; NPV: negative predictive value; PPV: positive 
predictive value; ROC: receiver operating characteristics; SE: standard error 
 
 
5. Discussion  
 
Middle-aged and old cats are often addressed to the veterinary clinic due to the 
presence of gastrointestinal symptoms, such as weight loss, anorexia, vomiting and 
diarrhea. In these patients, the diagnostic plan is complex and frequently leads to GI 
biopsy in order to obtain histological samples for diagnosis. Both IBD and AL are 
very common pathological conditions in cats, and they present a comparable clinical 
course14. The first step in the clinical evaluation of these patients is non-invasive 
routine laboratory testing and abdominal ultrasound examination14. Despite the fact 
that moderate to severe wall thickening, together with a loss of layering, presents a 
poor specificity, it is a highly suggestive ultrasonographic finding of neoplastic 
lesions (such as high-grade lymphomas); on the other hand, the wall appearance is 
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similar among low grade lymphomas and IBD25. In fact, both IBD and AL are 
characterized by diffuse or segmental distribution in the small intestine, with the 
ultrasonographic features of bowel wall thickening due to the increase in the 
muscularis propria and preservation of the wall layers without mass formation25. 
Moreover, a normal US examination does not rule out AL or IBD. However, in our 
study, cats with thickening of the muscularis propria detected on US and mesenteric 
lymphadenopathy were more likely to have lymphoma than IBD, and this is in 
accordance with another recent study26. 
The measurement of LDH as an initial screening for differentiating patients with 
different cancers (i.e. not only for lymphoma) and patients with non-oncological 
diseases has been used in dogs, but has not produced convincing results9. On the other 
hand, serum LDH levels demonstrated a prognostic value in canine lymphoma 
recurrence11 and an LDH increase was correlated with a worse prognosis in feline 
lymphoma, similar to the results observed in humans13. Therefore, assessing serum 
total LDH as a possible marker for AL may play an important role in differentiating 
between these two conditions in cats. 
The results of our study showed a statistically significant correlation between high 
serum total LDH values and AL in cats. In fact AL cats had significantly higher 
serum total LDH values than IBD cats (P = 0.017), as well as a significantly (P 
=0.002) higher frequency of cats with serum total LDH values higher than the upper 
reference limit was found in AL cats (n=16, 64.0%) compared to IBD cats (n=7, 
21.9%).  
In addition higher values of median total LDH near to the significant levels were 
found in cats with high grade AL and in those with B-lymphoma as well as a non 
significant higher frequency of abnormal LDH values was found in cats with severe 
IBD.  
As far as the gender and age classes are concerned, the spayed AL females, had 
significantly lower serum total LDH values than neutered AL males, while no 
significant differences have been found for gender in IBD cats. On the other hand, 
serum total LDH values were significantly higher in older than in younger IBD cats 
but not in the AL cats. Moreover, significantly higher values of LDH in AL versus 
IBD cats have been found in neutered males while in cats up to 7 years of age the 
difference was only close to the significant level. 
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The diagnostic accuracy in differentiating these two groups of cats in the population 
was significant, showing moderate sensitivity (68.0%) and specificity (78.1%). 
Gender (P=0.010) and age (P=0.014) significantly conditioned the diagnostic 
accuracy; in fact, significant values of accuracy were only found in neutered males 
(88.9%; P=0.002) and in cats up to 7 years of age it was particulary high even if it 
resulted being close to the significant level (91.7%; P=0.068). In particular, sensitivity 
prevailed both in netered males (88.9%) and in younger cats (100%) and a good 
values of NPV in both groups were detected (91.7% in neutered males and 100% in 
cats up to 7 years of age). The best cut-off for differentiating between AL and IBD 
cats was identified in a serum total LDH value ranging 239-243 U/L. 
It has been shown in the literature that cats over 7 years of age have an increased risk 
of tumors and that intact males and females appeared to have a decreased risk as 
compared with neutered patients, but this could be explained by the age difference 
among these patients as the older patients were more likely to be neutered23. We have 
only neutered cats in the study group and this is of course a limitation. Possible 
explanations of our findings might be that LDH levels are more sensitive to the 
presence of tumors in cats under 7 years of age since they have a lower probability of 
tumor. Despite these observations, the role that gender and age may play in 
differentiating AL from IBD cats needs to be analyzed in additional studies. 
As far as the relationship between breed and risk of tumor is concerned, an increased 
risk in the Siamese breed has been found23. There were no Siamese cats in our 
population; therefore, a confirmation of the role of LDH in specific breeds is needed 
involving larger samples. 
The main strength of the present study is the particular selection of cases made in a 
realworld setting according to a prospective protocol. Fixed previously-defined 
groups of AL and IBD cats were not studied but only those patients which, at the end 
of the blood and imaging screening for chronic GI symptoms, required biopsy in 
order to be diagnosed as having intestinal inflammation or lymphoma. Thus, the 
manifest cases of lymphoma, as well as those with other benign chronic enteropathies 
already suspected by means of the initial screening, were not included in the study in 
order to ensure that the results of the present paper could be reliably applied in 
clinical practice. 
The main limitation of the present study was the scarce sample size available due to 
the strict selection criteria applied. In particular, this weakness prevented the 
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possibility of better identifying the factors which play an independent role in affecting 
the differentiation between AL and IBD using multivariate analysis. In addition, a 
larger sample size would also have allowed us to reduce the gray zone of the best cut-
off values estimated in some subgroups of cats. Another limitation of the present 
study was the failure to include the histopathologic evaluation of the ileal bioptic 
specimens. New studies have now confirmed the need to collect both duodenal and 
ileal bioptic specimens in dogs and cats having diarrhea caused by intestinal 
inflammation (e.g., IBD) or tumour (e.g., lymphoma) in either the small or the large 
intestine27. Even though ileal biopsy yields important diagnostic information, 
ileoscopy is a more technically more demanding and time-consuming endoscopic 
procedure for many clinicians and, for this reason, the new endoscopic 
recommendations do not include the histopathologic review of ileal mucosal 
specimens in the initial screening for chronic GI symptoms28. Another limitation of 
the study is that the biopsy samples were analised by two patologists. 
In conclusion, although abnormal serum total LDH values measured at the initial 
screening were significantly more frequent in AL cats than in IBD cats, this test had 
moderate diagnostic accuracy (68.6%) in differentiating between these two conditions 
in the overall population. On the other hand, our study showed a good accuracy 
(88,9%) of serum total LDH in differentiating between AL and IBD in neutered males 
and in cats up to 7 years of age (91,7%) even if the diagnostic utility of LDH may 
warrant additional studies because of the small size of these subsets of patients. 
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1. Abstract  
 
In helical hydro-computed tomography (HHCT), water is used as a neutral luminal 
contrast medium together with intravenous iodine contrast medium for the diagnosis 
and staging of human gastric neoplasia. We evaluated the feasibility of HHCT in 11 
healthy animals (nine dogs and two cats). Adequate uniform gastric distension was 
obtained with 30 ml water/kg body weight. Fourteen client-owned dogs and four cats 
with suspected or diagnosed gastric neoplasia then underwent HHCT followed by 
intravenous contrast medium administration. Focal thickening with moderate contrast 
enhancement has been found in 10 dogs and 3 cats. The extent of the lesion was 
assessed easily in all these patients. Three dogs and one cat had a normal stomach 
wall. One dog had multifocal thickening of the antrum but no histopathologic 
diagnosis has been made. Helical hydro-CT, followed by intravenous contrast 
medium administration, is a simple technique for assessing the stomach wall.  
 
2. Introduction 
 
In humans, the diagnosis of gastric disorders is done by means of endoscopy and 
double-contrast radiographic studies, which enable the detection of small-sized 
lesions. However, these techniques only allow visualization of the mucosa, thus 
preventing the assessment of transmural and extraserosal extension of disease. 
Additionally, these techniques cannot detect metastases, which makes them unsuitable 
for tumor staging.
1 Therefore, transabdominal ultrasonography (US), computed 
tomography (CT), magnetic resonance (MRI) imaging and endoscopic ultrasound 
(EUS) are preferred for staging, mostly being used in combination, as none of these 
modalities alone is sufficiently accurate.
1, 2  
Standard CT examinations are limited in their usefulness for the diagnosis of gastric 
cancer due to the presence of gas and fluid artifacts and the difficulty of evaluating 
gastric wall thickening when the stomach is distended incompletely.
1 The accuracy of 
CT in the diagnosis and staging of gastric cancer improves when helical CT of the 
stomach is performed after the oral administration of water. This procedure, which is 
termed HHCT, is followed by the intravenous injection of contrast medium to 
enhance the image of the gastric wall.
1 In veterinary medicine, endoscopy and US are 
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most commonly used to evaluate gastric disorders.
3 Sonographically, wall thickening 
and wall layer identification are key features for the detection and characterization of 
gastric lesions, particularly to differentiate inflammatory and neoplastic lesions. 
Commonly, the stomach is empty during the US evaluation, which precludes accurate 
assessment of wall thickness.
4 Virtual endoscopy has not been widely assessed in 
companion animals and is not considered useful compared to conventional 
endoscopy.
5  
Our aims were to describe and optimize the technique for HHCT in dogs and cats and 
to evaluate the applicability of this technique in patients suspected of having a gastric 
tumour.  
 
3. Materials and methods  
 
Nine healthy female adult crossbreed dogs and two healthy female domestic shorthair 
(DSH) cats were studied to optimize the technique. Their body weight ranged from 5 
to 45 kg for the dogs and 3.5–4 kg for the cats. All owners gave their oral informed 
consent for the enrollment of their pets into the study. Ethical approval was not 
required since the animal involved in the study were scanned for orthopedical disease.  
The animals were fasted for 15 h before the examination. They were anesthetized 
with intravenous diazepam, followed by intravenous propofol. After endotracheal 
intubation, anesthesia was maintained with isofluorane and oxygen 
A single slice helical scanner has been used for the normal animal study∗. All the 
animals were in sternal recumbency and scanned from the caudal border of the heart 
to the left kidney. The slice thickness was 3 mm and the pitch was 2:1. The animals 
were hyperventilated during the procedure to produce temporary apnea for the 
purpose of reducing motion artifacts. Four different volumes of lukewarm water (10, 
20, 30, and 40 ml/kg) were given via a gastric tube, and CT images were acquired 
immediately after each volume was given. The whole procedure was performed over 
a period of 5 min to minimize gastric emptying between the different volume 
administrations. After the last water administration, the gastric tube was withdrawn 
partially and the CT study repeated after intravenous administration of 800 mg/kg of 
nonionic iodinated contrast medium with a power injector at 5 ml/s. Scanning was 
started about 30 s after the beginning of the contrast medium injection. All the studies 
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were reconstructed with 1 mm slice thickness and reviewed using soft tissue and bone 
algorithms.  
After the study of the normal animals, 14 adult dogs and 4 adult cats underwent 
helical-hydro CT. These 18 patients were all undergoing staging of confirmed (n = 
11) or suspected (n = 7) gastric neoplasia. They were each given 30 ml/kg of water 
via gastric tube, which was considered appropriate based on the study on the normal 
animals. The patients were imaged before and after the administration of intravenous 
contrast medium (800 mg/kg). Various scanners hsve been used, since this was a 
multicentric study. These included a single-slice CT* in seven dogs and one cat, a 16-
slice multidetector scanner† in six dogs and three cats, and a 4-slice multidetector 
scanner‡ in one dog. The slice thickness was 1.2–3.0 mm, depending on the machine. 
All the images of the normal and clinical animals were reviewed by a board-certified 
radiologist (M.V.), who was unaware of the histopathologic diagnosis in patients for 
which it was available. The seven patients with suspected neoplasia underwent 
endoscopic biopsy (n = 6) or US-guided biopsy (n = 1) to confirm or to exclude the 
CT diagnosis.  
 
4. Results  
 
In the healthy dogs and cats, the stomach wall appeared thickened before water 
administration because the stomach was collapsed and the gastric lumen was poorly 
visible, if at all. After the administration of 10 ml/kg, there was insufficient distension 
of the gastric wall in all the dogs and cats. The fundus was slightly distended, but the 
body, pyloric antrum and pyloric canal were still collapsed, thus preventing 
evaluation of the wall. After 20 ml/kg, the gastric wall was thinner in all regions. 
However, in the pyloric part and at the junction between the body and the pylorus, 
pronounced stomach folds were still visible and in contact with each other. With a 
total volume of 30 ml/kg, gastric distension was satisfactory, even though small rugal 
folds were still visible in the pyloric region and at the body-pyloric junction. After 40 
ml/kg, the stomach was distended and there were no rugal folds visible. All parts of 
the stomach could be assessed clearly with the 30 ml/kg and the 40 ml/kg distension. 
After intravenous administration of contrast medium, uniform moderate contrast 
enhancement of the gastric wall, especially of the mucosa, was observed (Figs. 1, 2A–
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F, and 3A–F). However, it was not possible to differentiate the layers of the gastric 
wall either before or after intravenous administration of the contrast medium. The 
comparison between the reconstructed images showed that the bone algorithm, 
despite its better spatial resolution, did not add further information.  
 
 
 
Fig 1. (A) Drawing of the stomach and (B) transverse CT image at the  same level. B, 
body; C, cardia; D, duodenum; E, esophagus; F, fundus; MaC, major curvature; MiC, 
minor curvature; P, pylorus; PA, pyloric antrum; PC, pyloric canal. 
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Fig 2. (A-F) Hydro-helical CT of a normal dog. (A) Native CT before administration 
of water. The fundus is filled partially with gas (asterisk) which allows evaluation of 
the wall at that location. The body, pyloric antrum and pyloric canal do not contain 
gas or fluid preventing adequate evaluation of the gastric wall. (B) After 10 ml/kg of 
water administration, only the proximal part of the fundus is distended adequately. 
The distal part of the fundus and the body have a small degree of distension but the 
rugal folds are still in contact. The other parts contain only a minimal amount of fluid. 
(C) After 20 ml/kg, the fundus and most part of the body are distended adequately. 
However, in the pyloric part and at the junction between body and pylorus, the 
distension does not allow optimal evaluation of the gastric wall. (D) After 
administration of 30 ml/kg of water, the degree of distension is satisfactory. Some 
folds are still visible in the body and pyloric parts of the stomach but they do not 
overlap. (E) After administration of 40 ml/kg of water, only a few folds are minimally 
still visible. A small amount of water is present in the duodenum (arrow). (F) After 
contrast medium administration there is moderate enhancement of the gastric mucosa. 
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Fig 3. (A–F) Hydro-helical CT of a normal cat. As for the dog, the stomach wall 
evaluation was not possible with the stomach empty (A) or after administration of 10 
ml/kg water (B) and suboptimal with 20 ml/kg water (C). Thirty milliliters per 
kilogram of water (D) was sufficient for diagnosis while with 40 ml/kg, all folds have 
disappeared. Figures (E) and (F) show the stomach after 40 ml/kg and plus contrast 
medium. Water within the duodenum is visible (arrow). 
Fourteen of the 18 patients with either histologically diagnosed or suspected gastric 
neoplasia had an abnormal gastric wall with HHCT. Further, histopathologic 
evaluation revealed gastric adenocarcinoma in eight dogs, low-grade leyomyosarcoma 
in one dog, and lymphoma in one dog and three cats. One dog with an abnormal 
gastric wall on CT did not undergo biopsy because of the owner’s refusal. Three dogs 
and one cat originally suspected of having a neoplastic lesion on US had a normal 
gastric wall on helical hydro-CT and neoplasia had been excluded on later 
histopathology.  
In the eight dogs with adenocarcinoma, the CT findings corresponded to a focal, 
moderate gastric wall thickening with inhomogenous contrast enhancement and 
hyperattenuating mucosa. The lesions were in the lesser curvature in five dogs, in the 
pyloric antrum in two dogs and in the fundus/body in one dog (Fig. 4A and B).  
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Fig 4. (A-B) CT studies of a dog with a gastric carcinoma: (A) CT scan with the 
stomach empty. There is a thickening of the gastric wall, especially at the level of the 
greater curvature at the body, and an irregular surface of the gastric mucosa of the 
lesser curvature of the body. (B) Same dog after distension with 30 ml water/kg and 
injection of intravenous contrast medium. The thickening of the lesser curvature at the 
body is clearly visible (arrows). The thickening of the gastric wall at the level of the 
lesser curvature of the body is clearly visible (arrow). There is moderate contrast 
enhancement. 
The dog with a low-grade leiomyosarcoma had a discrete round mass filling almost 
all of the pyloric antrum and marked peripheral contrast enhancement. One dog with 
lymphoma had a moderate circumferential thickening of the gastric body and fundus 
with moderate inhomogenous contrast enhancement of the lesion and 
hyperattenuating mucosa. Of the three cats with lymphoma, one had moderate to 
severe gastric wall thickening at the cardias/fundus, another at the lesser curvature, 
and the third at the fundus/body (Fig. 5A–B).  
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Fig 5. (A-B) Cat with gastric lymphoma. (A) Transverse image of an empty stomach–
shows a circumferential thickening of the gastric wall. (B) After administration of 30 
ml water/kg followed by intravenous contrast medium, a severe focal thickening of 
the greater curvature of the fundus and body with moderate contrast enhancement is 
visible. The gastric tube is visible (arrow). 
All three had moderate heterogeneous contrast enhancement of the lesion. One cat 
also had a hiatal hernia (Fig. 6A–C).  
 
 
Fig 6. (A) Sagittal and (B,C) dorsal reconstruected CT images at different levels of 
the stomach in a cat with gastric lymphoma. Severe irregular thickening of the fundus 
with a hiatal hernia is present (short arrows). The enhancement of the gastric wall is 
heterogeneous and moderate. The gastric tube is visible (long arrow). 
 
In the dog that did not undergo biopsies, a multifocal thickening at the pyloric antrum 
has been found, with marked contrast enhancement of the lesion and hyperattenuating 
mucosa.  
Three dogs and one cat had a normal gastric wall on CT, thus excluding a neoplastic 
lesion. Multiple biopsies of the stomach wall have been taken, and histopathologic 
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evaluation confirmed the absence of neoplasia. In two dogs, the gastric lymph nodes 
were enlarged, and heterogeneous, and were found to be metastatic.  
No adverse effects of the procedure were detected.  
 
5. Discussion  
 
Helical CT with water-filling of the gastric lumen followed by the administration of 
intravenous contrast medium has led to improvement in the detection and 
characterization of gastric cancer (GC) in humans
6 and is the method of choice for 
preoperative imaging of gastric carcinoma.
7 The main CT findings of gastric cancer 
are local or diffuse thickening of the gastric wall with variable contrast enhancement 
and an intraluminal soft tissue mass. Tumours can also infiltrate into perigastric 
tissue, encroach on adjacent organs and metastasize to distant sites.  
We found that the wall of the normal collapsed, empty stomach appeared thickened 
before the administration of water, thus preventing the performance of reliable 
evaluation. After distension of the stomach with 30 ml water/kg body weight, all parts 
of the stomach could be satisfactorily assessed. The administration of intravenous 
contrast medium after the administration of water led to hyperattenuation of the 
mucosa in all normal dogs.  
In the clinical patients, the thickening of the gastric wall on HHCT has been highly 
indicative of a gastric tumour in 14 of the 18 patients, and the absence of thickening 
excluded a tumour in 4 of the 18 patients. Seventeen of 18 patients had the diagnosis 
confirmed by histopathologic examination. Intravenous contrast studies in the clinical 
patients have been characterized mainly by heterogeneous contrast enhancement of 
the mass with a hyperattenuating mucosa. A specific pattern that would have enabled 
differentiation of the different types of gastric tumours has not been found.  
The intravenous contrast study is mandatory for tumor staging to assess the presence 
of metastasis in lymph nodes and various other perigastric organs. In humans, the 
accuracy of HHCT is acceptable for staging of distant metastasis, but inadequate for 
staging lymph node metastasis of gastric carcinoma.
8 Helical hydro-CT also has a 
higher (86.0%) accuracy than that of conventional CT (72%) for staging GC.
6 In this 
study, two dogs had enlarged gastric lymph nodes that appeared to be metastatic on 
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cytologic examination. Nonetheless, HHCT is very useful for choosing between 
tumor resection and conservative treatment in patients with gastric tumours.  
Helical hydro-CT can provide useful information about the location and extent of 
gastric lesions, as was shown in our study, and if surgery is an option. Helical hydro-
CT is also valuable for excluding a gastric lesion suspected on other imaging 
modalities. In this study, three dogs and one cat suspected of having a gastric tumour 
on US had a normal stomach on HHCT. However, the US studies were performed 
without dilation of the stomach by water, which may explain the different 
interpretation. However, it is more relevant to compare native US with HHCT. The 
main advantage of US compared to CT is that it can be performed with no, or less, 
chemical restraint. Having to anesthetize the patient to administer water for US would 
clearly diminish the biggest advantage of this US in comparison with CT.  
In veterinary medicine, the most frequent modalities used to study gastric lesions are 
US and endoscopy.
3, 4 Although we did not perform a direct comparison of these 
techniques with HHCT, we feel that HHCT could be superior to US and endoscopy in 
evaluating the location and local invasiveness of the lesion. On the other hand, US 
and endoscopy are probably superior in doing adequate biopsies.  
Another possibility for dilating the stomach and studying the gastric wall more 
accurately with CT would be filling the stomach with air. However, this technique 
cannot be standardized because it is not possible to predict or measure the quantity of 
air that escapes from the stomach. Additionally, the use of air carries the theoretical 
risk of vascular embolization or gastric volvulus. With the use of water, no 
complications have been observed. Reasonable amounts of water simply pass through 
the stomach, as usual.  
The images reviewed with a bone algorithm did not add further information, therefore 
it appears that a standard algorithm can be satisfactory for this technique.  
In conclusion, HHCT is easy to perform and is useful for the diagnosis of gastric 
tumours in dogs and cats. The recommended dose of water is 30 ml/kg, and the 
HHCT study should be followed by the administration of intravenous contrast 
medium. Adequate distension of the stomach and optimally timed administration of 
intravenous contrast medium are mandatory to obtain high quality images and to 
detect and characterize the disease process. 
∗GE ProSpeed Power, Milwaukee, WI.  
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The evaluation of clinico-pathological parameters and imaging diagnostics are the 
basis of the protocol in dogs and cats with gastric and intestinal tumors since they 
guide the clinician towards the diagnosis and the staging of a complex disease. 
Histopathologic diagnosis is the final aim of the diagnostic protocol but it is also the 
beginning of some important evaluations which influence therapy and prognosis. 
 
In the first part of this study, 19 histopathological samples of gastric epithelial 
neoplasia in dogs have been analyzed: 5 adenomas and 14 carcinomas. Five (35.7%) 
carcinomas have been classified as intestinal and 9 (64.3%) as diffuse. They were 
retrospectively evaluated for EGFR/HER-2 immunohistochemical expression and 
KRAS mutational status. In human oncology, the importance of the EGFR/HER-
2/KRAS signaling pathway in gastric cancer has been well established, and HER-2 
testing is required before starting therapy. Conversely, this pathway has never been 
investigated in canine gastric tumours. 
Gastric tumours account for <1% of all reported neoplasms in dogs.1 Carcinoma is the 
most frequent type of gastric tumour, comprising 50-90% of all canine gastric 
malignancies and usually resulting in death.2 The majority of canine gastric tumours 
are located in the lesser curvature and pylorus, often progressing to involve most of 
the stomach body.2 The reported age range of dogs with gastric tumour is from 3 to 16 
years of age (mean 7.5 years) and, as in humans, a higher incidence is reported in 
males.3 Breed predisposition to gastric tumour in Belgian shepherd dogs (Tervuren 
and Groenendael), rough collies, Staffordshire terriers, chowchows and standard 
poodles has been reported.4,5 Sled dogs (e.g., Alaskan malamutes, Siberian huskies, 
Pyrenean Mountain dogs) and Japanese akitas are often affected (unpublished data);6 
however, in determining any canine breed predisposition, the popularity of the breeds 
in the specific geographical location must be considered. 
The incidence of gastric cancer is lower in dogs than in humans but, in recent years, 
this disease appears to have been diagnosed more frequently. This likely reflects the 
use of more accurate diagnostic techniques, such as endoscopy. Despite this, canine 
gastric tumours are often diagnosed in advanced stage, resulting in a poor prognosis 
and limited treatment options.6 A median survival time of 35 days has been described 
and, in approximately 70-90% of cases, the tumours have already metastasized at the 
time of diagnosis or death.6 Metastatic sites include the gastric lymph nodes, 
omentum, liver, duodenum, pancreas, spleen, oesophagus, adrenal glands and lungs.6 
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Most canine gastric tumours produce localized or diffuse thickening and/or ulceration 
of the gastric wall, serosal pallor and, occasionally, a substantial decrease in the 
number of rugae on imaging and gastroscopy.7 
In humans, the development of gastric carcinoma often involves a sequence of events, 
starting with mild non-atrophic gastritis and progressing through stages of chronic 
atrophic gastritis, intestinal metaplasia, dysplasia and, ultimately, gastric 
adenocarcinoma.8 In veterinary medicine, this sequential pathogenesis has not yet 
been defined, although metaplastic and dysplastic changes have also been recognized 
in the canine stomach. Canine gastric neoplasia has been well described and is now 
beginning to be explored at the molecular level. In human medicine, understanding 
the molecular events and pathways in gastric cancer has led to advances in 
prevention, early diagnosis, tumour classification and therapeutic intervention. A 
collections of genetic and molecular abnormalities occurring during gastric 
carcinogenesis has been described in detail, including the activation of oncogenes, 
overexpression of growth factors receptors, inactivation of tumour suppression genes, 
involvement of DNA repair genes and cell adhesion molecules, loss of heterogeneity 
and point mutations of tumour suppressor genes and the silencing of tumour 
suppressors.9 In veterinary pathology, the first steps towards molecular studies are 
being taken. Reduced sampling, and the difficulty in validating and optimizing 
molecular biology techniques in animal tissues and samples could account for this 
delay. Nevertheless, some studies have been carried out in this area and often 
replicate the results which have been obtained in human pathology since strong 
similarities have been observed between dogs and humans with regard to the clinical 
presentation and the histopathological features of GC. Janke et al. tested 16 canine 
gastric tumours and found an overexpression of C2-OsLe(x) in 56% of the tumours 
when compared with normal gastric mucosa.10 The authors hypothesized that these 
carbohydrates are highly expressed in more malignant types of canine gastric tumour; 
they promote adhesion to selectins and attachment of cancer cells to the vascular 
endothelium, and, therefore, metastasis.10  
The type I growth factor receptor family consists of the prototype EGFR and the 
related members cerbB-2, c-erbB-3 and c-erbB-4 (also known as HER1, HER2, 
HER3 and HER4, respectively).10 The membrane receptors have been shown to be 
important in the development of neoplasia.10 The HER3 molecule differs from the 
other members of this family because it has little or no tyrosine kinase activity.10 In 
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humans, the blockade of HER-3 activity decreased downstream signaling of the 
phosphoinositide 3-kinase/protein kinase B pathway and the cell cycle, resulting in 
the death of tumour cells. Previous investigations have suggested a close relationship 
between cytoplasmic/membrane HER3 expression and tumour prognosis for human 
gastric cancer. Doster et al. determined CDX2 (a specific marker for human cell 
adenocarcinoma) and HER3 expression in five canine gastric mucinous 
adenocarcinomas.11 In all cases, strong cytoplasmic HER3 labelling has been 
recorded in >10% of the tumour cells, and the majority of the nuclei of the neoplastic 
cells showed strong CDX2 expression.11 However, in this study, CDX2 and HER3 
expression could not be correlated with prognosis due to the small population size and 
the lack of a complete clinical history and postsurgical follow-up.11 A recent study in 
dogs focused on other members of this family; EGFR and its analogue HER2 and 
KRAS, which is a small protein encoded by the KRAS gene mediating the 
transduction of signals between EGFR receptors and the nucleus.12 In human 
oncology, it has been shown that the KRAS gene can undergo mutation, the majority 
of which involve codons 12 and 13 identified as predictors of resistance to anti-EGFR 
drugs. Our study evaluated EGFR/HER2 immunoexpression and KRAS mutational 
status retrospectively in five adenomas and 14 carcinomas (5 intestinal and 9 diffuse 
carcinomas). Overexpression of EGFR and HER-2 has been observed in 42.1% and 
57.9% of the cases, respectively, regardless of tumour location and biological 
behaviour. The percentage of EGFR-positive tumours was significantly higher in the 
intestinal type than in the diffuse type. Furthermore, the KRAS gene was of wild type 
in 18 cases while one infiltrative mucinous carcinoma of the gastric fundus with 
regional lymph node metastases harboured a point mutation at codon 12. This 
mutation is among the most frequently detected in humans and leads to the 
substitution of a glycine by an arginine, thus leading to a geometric alteration of the 
protein. This results in a lack of quanine triphosphate hydrolysis, which keeps KRAS 
in a permanently activated state.13 
Genetic and/or epigenetic alterations in the E-cadherin-encoding gene (CDH1), or 
alterations in its protein expression, often result in tissue disorder, cellular de-
differentiation, increased invasiveness of tumour cells and ultimately turns into 
metastasis.13 In humans, CDH1 is regarded as a classical tumour suppressor gene in 
gastric carcinogenesis, being involved in the initiation and progression of both 
sporadic and hereditary forms. The potential role of E-cadherin (E-cad) and CDH1 in 
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canine GC has been investigated. Preliminary results show that the majority of canine 
gastric tumours have abnormal E-cad expression in comparison with the normal 
gastric mucosa. The different patterns of E-cad immunoexpression observed in canine 
GC are similar to those already described in human gastric cancer and the existence of 
CDH1 somatic alterations in such lesions may provide useful information for the 
clinical management and prognosis for these animals.13 In another study, the 
expression of gastrin was investigated immunohistochemically in gastric biopsy 
samples from 64 dogs with gastric tumour. Only 8% of the canine carcinomas 
demonstrated expression of gastrin, which is considered less common than in humans. 
The authors concluded that this may not be a reliable prognostic marker in dogs.14 
 
In the second part of this study, the diagnostic utility of measuring serum lactate 
dehydrogenase in cats with inflammatory bowel disease and alimentary lymphoma, 
which are common gastrointestinal diseases in cats, have been evaluated. 
From literature it is known that, in cats with lymphoma, an increase in LDH is a 
negative prognostic survival factor associated with cellular necrosis.15 In this study, 
serum LDH has been measured in a population of cats with the same chronic 
gastrointestinal symptoms.15 AL and IBD are two pathological conditions which 
overlap from a symptological point of view and we aimed to measure the value of the 
enzyme and evaluate whether it can be useful in differentiating these two specific 
diseases. 
In human primary gastric lymphoma, elevated LDH was associated with a poor 
outcome.16 Both IBD and AL are very common pathological conditions in cats, and 
they present a comparable clinical course. The first step in the clinical evaluation of 
these patients is non-invasive routine laboratory testing and abdominal 
ultrasonograhic examination.17 Despite the fact that moderate to severe wall 
thickening, together with a loss of layering, shows poor specificity, it is a highly 
suggestive US finding of neoplastic lesions (such as high-grade lymphomas); on the 
other hand, the wall appearance is similar among low grade lymphomas and IBD.18 In 
fact, both IBD and AL are characterized by diffuse or segmental distribution in the 
small intestine, with the ultrasonographic features of bowel wall thickening due to the 
increase in the muscularis propria and the preservation of the wall layers without mass 
formation.18 Moreover, a normal US examination does not rule out AL or IBD. 
However, in our study, cats with a thickening of the muscularis propria detected on 
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US and mesenteric lymphadenopathy were more likely to have lymphoma than IBD; 
this is in accordance with another recent study.19 The measurement of LDH as initial 
screening for differentiating patients with different cancers (i.e. not only for 
lymphoma) and patients with non-oncological diseases has been used in dogs, but has 
not produced convincing results.15 On the other hand, serum LDH levels have been 
demonstrated to have a prognostic value in canine lymphoma recurrence20 and a LDH 
increase was correlated with a poorer prognosis in feline lymphoma, similar to the 
results observed in humans.21 Therefore, assessing serum total LDH as a possible 
marker for AL may play an important role in differentiating between these two 
conditions in cats. The results of our study showed a significant correlation between 
high serum total LDH values and AL in cats; in fact, approximately 64% of the AL 
cats had abnormal LDH values as compared with 21,9 % of the IBD cats. In addition 
higher values of median total LDH close to the significant levels have been found in 
cats with high grade AL and in those with B-lymphoma as well as a non significant 
higher frequency of abnormal LDH values was found in cats with severe IBD. As far 
as the gender and age classes are concerned, the spayed AL females, had significantly 
lower serum total LDH values compared to neutered AL males, while no significant 
differences have been found for gender in IBD cats. On the other hand, serum total 
LDH values were significantly higher in older than in younger IBD cats but not in the 
AL cats. In addition, significantly higher values of LDH in AL versus IBD cats have 
been found in neutered males while in cats up to 7 years of age the difference was 
only close to the significant level. The diagnostic accuracy in differentiating these two 
groups of cats in the population was significant, showing moderate sensitivity 
(68.0%) and specificity (78.1%). Gender (P=0.010) and age (P=0.014) significantly 
conditioned the diagnostic accuracy; in fact, significant values of accuracy were only 
found in neutered males (88.9%; P=0.002) and in cats up to 7 years of age it was 
particulary high even if it resulted close to the significant level (91.7%; P=0.068). In 
particular, sensitivity prevailed both in netered males (88.9%) and in younger cats 
(100%) and a good values of NPV in both groups have been detected (91.7% in 
neutered males and 100% in cats up to 7 years of age).  
Some authors have recently tested the use of supervised machine-learning algorithms 
to differentiate between the 2 diseases using data generated from noninvasive 
diagnostic tests. Complete blood count (CBC) and serum chemistry (SC) results for 
the following 3 groups of client-owned cats were analyzed: normal, IBD or AL.22 For 
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GI diseases, and specifically for IBD and AL, previous studies have shown some 
common hematological and biochemical abnormalities. Hypoalbuminemia, the most 
common serum biochemical abnormality in cats with lymphoma, is thought to be a 
result of the disruption of intestinal wall integrity. Therefore, albumin is one possible 
analyte which could help to differentiate between IBD and AL. In previous studies, 
basic statistical analyses have shown laboratory differences between normal cats and 
cats with IBD and AL. Cats with IBD or AL tended to have mild non-regenerative 
anemia attributed to chronic disease and suppression of hematopoiesis as previously 
found. Few differences were identified as possible discriminators using traditional 
comparative statistics between the AL and IBD groups except for chloride and 
cholesterol. Prediction models using machine learning provided a method for 
differentiating between AL-IBD, AL-normal, and IBD-normal. These models can 
provide another non-invasive diagnostic tool to assist clinicians with differentiating 
between IBD and AL, and between diseased and non-diseased cats.22 
The need for non-invasive markers for differentiating diseases from such an 
overlapping clinical presentation surely exists. Additional studies are necessary for an 
in-depth study of the subject. To date, the only thing known with certainty is that an 
elevated percentage of cats with clinical signs of chronic disease of the small intestine 
and ultrasonographic findings of thickening of the intestinal wall can have both 
chronic enteritis and an intestinal lymphoma.23 
 
In the third part of this study, a diagnostic imaging method, namely HHCT has been 
studied.  
Radiology without contrast medium is easily available but has scarce diagnostic value 
for gastrointestinal neoplasia. Using contrast medium certainly adds much more 
information but it is a complicated and time-consuming method. Abdominal 
ultrasonography and endoscopy are the most adequate imaging techniques for 
imaging gastric neoplasia in veterinary medicine.24 Ultrasonography is non-invasive, 
and endoscopy is minimal invasive method that is of low risk for the patient. Besides 
for diagnosing gastric neoplasia, US is also used for studying lymph nodes and the 
intestines. Under US guidance, fine needle aspiration (FNA) of the tumour for 
cytological diagnosis is possible prior to endoscopy. However, US evaluation of the 
stomach can be limited due to the presence of gas or food within the lumen which 
create artifacts impeding thorough evaluation of the stomach wall.24 The absence of 
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abnormal US findings does not exclude the presence of serious GI disease. 
Additionally, the ability to properly identify the correct location of a mass can be 
challenging when using US due to its dynamic nature and lack of consistent, well-
defined anatomic landmarks.26 Ultrasonographic examination of the stomach can be 
carried out by means of changing the position of the patient or by filling the stomach 
with a liquid, which is not easy to perform in veterinary medicine.  
The US diagnosis must be confirmed by means of upper digestive endoscopy which 
permits direct visualization of the stomach. Undoubtedly, endoscopy is the best 
method for evaluating the gastric mucosa. The location of a gastric tumour is more 
easily assessed using endoscopy due to more established anatomic landmarks and the 
ability to visualize the entire luminal surface.26 In a recent study, the authors 
compared the US and the endoscopic findings in a group of dogs and cats with 
histologically confirmed gastric neoplasia.27 Endoscopy identified 95% gastric 
tumours compared to 50% for ultrasonography.27 The agreement between the 
techniques for tumour location was only 36%.27 Endoscopy is also the best method 
for obtaining biopsies for histopathological examination and permits the removal of 
pedunculated masses. Endoscopic biopsy is not an invasive procedure, requiring little 
time and is very adapted to critical patients; furthermore, it identifies the sites of the 
mucosa which are most suitable for biopsy. The results obtained from endoscopic 
biopsy depend on the experience of the operator and the equipment used.28 However, 
ultrasonography is also operator-dependent. One disadvantage of endoscopy is that 
samples cannot be obtained from nonfasting patients and it is not always possible to 
reach the ileum, even for an expert operator. The “blind” biopsy technique of the 
ileum through the ileocolic sphincter is, however, possible. Some studies show a 
greater probability of diagnosing AL in cats by means of a full thicknesses 
laparatomic or laparoscopic biopsy respect to an endoscopic biopsy.29,30 However, it 
can be said that comparative studies which document the superiority of one biopsy 
technique respect to another have not been published in the literature. Surely, 
specimens from many segments of the intestine increase the sensitivity of a diagnosis 
of AL and of other GI diseases. All thickness surgical biopsy is indicated if 
involvement of the submucosa/musculature is suspected or if the results obtained with 
the endoscopic biopsy are not correlated with the clinical results.31 In another study 
evaluating endoscopic biopsies and full thickness biopsies in cats with AL and IBD, 
approximately one third of the cats with AL were incorrectly diagnosed with 
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endoscopic biopsies.29 This limitation of endoscopic biopsy is due to the small tissue 
samples achievable with endoscopic bioptic forceps which are unable to reach the 
deeper layers of the stomach or intestinal wall.32 If the lesion is identified on 
ultrasonographic examination, evaluation of the depth of the gastric wall changes may 
provide beneficial information before endoscopy and biopsy.25,33,34 
The type of gastric neoplasia that is the most frequently missed by US is lymphoma. 
Five different small intestinal sonographic patterns of lymphoma distribution have 
been described in cats, including transmural-circumferential, transmural-segmental, 
transmural-nodular, transmural-bulky and mucosal infiltration.34 In fact, the mucosal 
infiltration pattern can present a normal aspect of the gastric wall in the early phases 
of the disease due to the minimal mucosal thickening with normal parietal 
stratification.35 This pattern may also produce a normal US image in the early stage of 
the disease and, therefore, it may not be identified on US examination. 
A distinction in the US appearance of T-cell lymphoma in the small intestines has 
been made on the basis of thickening of the muscularis layer only.18 Feline GI small 
cell T-cell lymphoma is becoming recognized as a distinct form of GI AL in cats, and 
appears similar to IBD on ultrasound and histology18. Both IBD and AL are 
characterized by diffuse or segmental distribution in the small intestine, with US 
features of bowel wall thickening owing to a diffuse circumferential thickening of the 
muscularis propria and preservation of wall layers without mass formation. In the 
latter study18, the muscularis propria was twice as thick in the intestinal segments with 
lymphoma and IBD than in healthy cats, and was the major contributor to overall 
bowel wall thickening. A relationship between the thickness of the muscularis layer 
and the extent of the neoplastic lymphocytic infiltration has previously been 
described, with the muscularis thickening increasing the odds of transmural disease in 
the depth of the submucosa.19 The ratio of the muscularis propria to the submucosa 
may serve as a useful marker for possible infiltration with lymphoma or IBD on US 
examination. Healthy cats had a ratio of <1 in the duodenum, and the majority of 
healthy cats had a ratio of <1 in the jejunum. In contrast, the ratio of the muscularis 
propria to the submucosa in the majority of cats affected with lymphoma was >1 and 
significantly higher in both segments. This measurement may be useful in identifying 
cats with muscularis propria thickening in addition to absolute measurements.  
Another study compared the wall layering of cats with IBD to those with intestinal 
AL, and found no US differences between the two diseases.18 A previous study found 
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a stronger association between muscularis thickening and lymphoma than muscularis 
thickening and IBD when considering the prevalence in each population.19 Both 
disease groups were clearly different from the population of healthy cats, and the ratio 
of muscularis propria to submucosa of >1 was indicative of small intestinal disease. 
Diffuse thickening of the muscularis layer of the small intestine with concurrent 
enlargement of the colic lymph nodes was associated with small cell T-cell GI 
lymphoma, although lymph node enlargement was not necessarily diagnostic for 
metastatic disease.18 
When considering the computed tomography features of alimentary limphoma, in 
low-grade lymphomas there is less severe gastric wall thickening than in high-grade 
lymphoma, and abdominal lymphadenopathy is less common. The absence of 
abnormality or the presence of just minimal gastric wall thickening or a shallow 
lesion at CT suggests low-grade mucosa associated lymphoid tissue (MALT) 
lymphoma, subsequently CT is of limited value in its diagnosis. Hydro-helical CT 
(HHCT) refers to stomach CT with water distension. Compared to CT-gastrography 
with air distension, HHCT is believed to be less affected by artifacts caused by 
intraluminal air and is likely to demonstrate detailed mucosal enhancement of cancer 
foci. Traditionally, both air and tap water have been used as oral contrast agents to 
achieve adequate gastric distension for preoperative CT imaging in patients with early 
gastric cancer (EGC). CT is most frequently used for staging GC. Helical CT in 
combination with the water-filling method (HHCT) has led to marked improvement in 
the detection and characterization of gastric cancer. The main CT findings of GC are 
local or diffuse thickening of the gastric wall with variable enhancement and 
intraluminal soft tissue mass. The accuracy of HHCT (86.0%) in one study was higher 
than that of conventional CT (72%).36 Tumour-node-metastasis (TNM) staging using 
HHCT depends on the improvement of CT equipment and stomach filling with water. 
Contrast-enhanced HHCT can additionally improve the accuracy of GC staging 
before surgery. In conclusion, the primary pathological condition of GC and its 
metastasis to adjacent or distant structures can be demonstrated by contrast-enhanced 
HHCT. HHCT can provide more information for surgeons to formulate an appropriate 
therapy for gastric cancer patients. A more recent study shows that, despite the 
introduction of multidetector row CT techniques and the use of multiplanar 
reconstruction (MPR) images, the detection rate of EGC on HHCT has still been 
unsatisfactory. Tumour size and invasion depth were independent factors for the 
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visibility of EGC on HHCT.37 Double contrast radiography in humans is a overcome 
technique with the coming of endoscopy. In literature there’re no comparison for 
diagnostic accuracy between contrast radiography and CT. To date, methods for more 
complex images, such as CT and MRI, have not been used for diagnosing 
gastrointestinal tumours in dogs and cats. 
We evaluated the feasibility of HHCT in 11 healthy animals (nine dogs and two cats). 
Adequate uniform gastric distension was obtained with 30 ml water/kg body weight.  
After optimizing the technique, 14 dogs and 4 cats with suspected or diagnosed 
gastric neoplasia underwent HHCT followed by intravenous (IV) contrast medium 
administration. Focal thickening with moderate contrast enhancement of the wall was 
found in 10 dogs and 3 cats. The extent of the lesion was assessed easily in all the 
patients. HHCT, followed by IV contrast medium administration, is a simple 
technique for assessing the stomach wall in dogs and cats; it is easy to perform and is 
useful for diagnosing gastric tumours. The recommended dose of water is 30 ml/kg, 
and the hydro CT study should be followed by the administration of IV contrast 
medium. Adequate distension of the stomach and the optimally timed administration 
of intravenous contrast medium are mandatory for obtaining high quality images and 
for detecting and characterizing the disease process.  
HHCT can provide useful information regarding the location and extent of gastric 
lesions, as was shown in our study, and whether surgery is an option. The technique is 
also valuable for excluding a suspected gastric lesion seen on other imaging 
modalities. 
 
Future research studies 
In recent years, a significant focus on the identification of biomarkers for early 
detection of gastrointestinal tumors has been observed in men. In gastric cancer 
conventional tumor markers do not allow diagnosis with adequate sensitivity and 
specificity; their use is limited to prognosis and follow-up recommendations 
determining the ideal treatment for an individual. However, several studies presently 
underway are attempting to establish new molecules as tumor markers. It is also well 
known that various genetic alterations, activation of oncogenes, inactivation of tumor 
suppressor genes, are necessary stages in gastric and intestinal cancer development. 
In veterinary pathology the first steps towards molecular investigations are being 
taken. The reduced sampling and the difficulty in validating and optimizing molecular 
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biology techniques in animal tissues and samples could underlie this delay. 
Nevertheless, some studies have occurred in this area and often replicate results 
obtained in human pathology, like studies on CDX2, HER-3 and E-cadherin-encoding 
gene (CDH1). Strong similarities have been observed between both dogs and people 
with regard to the clinical presentation and histopathological features of GC. Future 
research study probably will be in the direction of identification of tumor biomarkers 
and molecular genetic behavior of these tumors.  
 
Over the past two decades, advances in cross-sectional imaging, such as CT and MRI 
have dramatically changed the concept of GI imaging. Next to HHCT, these 
modalities offer additional diagnostic tools. CT-enterography performed after the oral 
administration of an isotonic solution in order to obtain adequate distension of the 
small bowel wall is the intestinal counterpart of HHCT and could provide a new 
insight in intestinal tumours. MRI has played a secondary role for years when 
compared to CT, especially due to the increased length of time of acquisition and the 
motion artifacts. However, the rapid development of the technical innovations, the 
introduction of new equipment and higher gradient magnetic fields have allowed the 
development of fast T1- and T2-weighted sequences with improved spatial and 
temporal resolution, single-shot fast spin-echo or gradient-echo, acquired during a 
single apnoea, which enabled the development of MRI protocols for studying the 
small bowel using an intraluminal contrast medium (MR-enterography). Finally, 18F-
fluorodeoxyglucose PET/CT has proved to be useful in the management of gastro-
entero-pancreatic tumours in humans and would be an interesting tool to study in 
veterinary medicine. Other new advanced imaging techniques, including 
magnification endoscopy, dye-based and dyeless chromoendoscopy and 
endomicroscopy provide real-time insights into the ultrastructural assessment of 
mucosal inflammation and dysplasia in humans.  
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Gastrointestinal (GI) neoplasia is not common in dogs and cats, with gastric tumours 
representing <1% and intestinal tumours <10% of overall neoplasia in these species. 
Gastrointestinal neoplasia tends to be malignant. The average age of dogs with GI 
neoplasia is 6–9 yr and of cats 10–12 yr. Adenocarcinomas are the most common GI 
neoplasia in dogs; lymphoma is the most common feline GI neoplasia. Early 
diagnosis is important as it may improve prognosis and life quality, nevertheless 
timely detection remains challenging in current veterinary practice. Therefore, the 
development of new methods to improve the diagnosis, prognostic capabilities or 
treatment approach is essential. Over-expression of “oncogenes”, increased enzymatic 
activity and new imaging methods have been explored to provide an improved 
approach of GI tumours.   
 
In Chapter I, the most common GI tumours are described, based on their clinical 
presentation and histological types. The clinico-pathological parameters used for 
diagnosis are briefly discussed and compared to their use in human medicine. Finally, 
the current imaging methods for diagnosis of GI tumours are described. For the 
moment, ultrasonography (US) is the most used imaging modality. Depending on the 
localization of the pathological process, it can prove useful to combine US with 
endoscopy. These modalities have progressively replaced the labour-intensive 
radiographic contrast studies. Computed tomography (CT) and MRI can also deliver 
useful information, but their use is currently limited compared to US and endoscopy.  
 
The scientific aims of this thesis are presented in Chapter II. The final goal of this 
work is to provide new insights for the diagnosis of GI tumours in dogs and cats. In 
the first part of this thesis, the role of a protein tyrosine kinase erbB-2, frequently 
called HER2 - as a biomarker for GI tumours is studied. In the second part, the 
enzymatical activity of LDH in tumours versus in inflammatory processes is studied. 
In the third part, the feasibility, use and capabilities of a new imaging method, helical 
hydro-computed tomography (HHCT) are assessed.  
 
The importance of the EGFR/HER-2/KRAS signaling pathway in gastric tumours is 
investigated in Chapter III. Canine gastric epithelial neoplasms (5 adenomas and 14 
carcinomas) were retrospectively assessed for EGFR/HER-2 immunohistochemical 
expression and KRAS mutational status. A high expression of EGFR and HER-2 in 
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canine gastric epithelial tumours, suggesting a role of these receptors in 
carcinogenesis, especially when compared to the persistent negativity of normal 
gastric mucosa, was noted. Additionally, there was a significantly higher percentage 
of EGFR positive cases among intestinal-type carcinomas. Unlike in humans, a 
relationship between marker expression and anatomical location or the biological 
behaviour of tumours has not been observed. Finally, a codon 12 mutation in the 
KRAS gene has been identified, equivalent to that found in human gastric carcinomas, 
suggesting that this altered pathway may also exert a role in the pathogenesis of 
gastric tumours in dogs. 
 
The potential use of an elevation of the serum total LDH in cats to differentiate 
alimentary lymphoma (AL) from non-neoplastic GI disease, such as IBD, was 
analyzed in Chapter IV. A prospective non-randomized controlled study was carried 
out in three Italian private veterinary clinics. Fifty-seven client-owned cats (25 
lymphomas, 32 IBD) have been used in a prospective non-randomized controlled 
study. Serum samples of total LDH analysis were measured. Although abnormal 
serum total LDH values were measured at the initial screening in cats with AL 
compared to IBD, this test had fair diagnostic accuracy in differentiating between 
these two conditions in the overall population. On the other hand, the study showed a 
good accuracy (P=0.001) of serum total LDH in differentiating between AL and IBD 
in neutered males, and in cats up to 7 years old the difference was close to the 
significant level (P=0.088). 
 
In Chapter V, the technique of HHCT has been described and optimized for use in 
dogs and cats, and its applicability in patients suspected of having a gastric tumour 
has been assessed. Nine healthy female adult crossbreed dogs and two healthy female 
domestic shorthair (DSH) cats have been studied to optimize the technique. After the 
study on the normal animals, 14 adult dogs and 4 adult cats with confirmed (n=11) or 
suspected (n=7) gastric neoplasia underwent HHCT. We concluded that HHCT is 
easy to perform and is useful for the diagnosis of gastric tumours in dogs and cats. 
The recommended dose of water is 30 ml/kg, and the HHCT study should be followed 
by the administration of intravenous contrast medium. Adequate distension of the 
stomach and optimally timed administration of intravenous contrast medium are 
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necessary to obtain high quality images and to detect and characterize the disease 
process.  
 
Chapter VI contains the general discussion and conclusions of this thesis. Despite 
some limitations, this study has demonstrated the potential use of new approaches in 
improving our diagnostic capabilities, providing new means for better prognosis and 
therapy in patients with GI tumours. 
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Gastro-intestinale (GI) neoplasie komt maar zelden voor bij honden en katten, bij 
dewelke maagtumoren <1% en darmtumoren <10% van het totale aantal neoplasie 
gevallen uitmaken. GI neoplasie is maar al te vaak maligne. De gemiddelde leeftijd 
bij honden met GI neoplasie ligt op 6-9 jaar, en bij katten op 10-12 jaar. 
Adenocarcinomen zijn de meest voorkomende vorm van GI neoplasie bij honden; 
lymfomen komen het vaakst voor bij katten. Een vroege diagnose is essentieel, gezien 
het grote effect op prognose en levenskwaliteit, doch een tijdige opsporing blijkt 
moeilijk in de huidige diergeneeskundige praktijk. Bijgevolg zouden de over-
expressie van de zogenaamde ‘oncogenen’, toegenomen enzymatische activiteit en 
nieuwe beeldvormingsmethoden grondig verkend moeten worden om een meer 
efficiënte benadering van GI tumoren te bereiken. 
 
In Hoofdstuk I, worden de meest voorkomende gastro-intestinale tumoren 
beschreven, op basis van klinisch beeld en histologisch type. De klinisch-
pathologische parameters die gebruikt worden voor de diagnose, worden kort 
besproken en vergeleken met hun rol in de humane geneeskunde. Tenslotte wordt een 
overzicht gegeven van de beeldvormingsmethoden die actueel ingeschakeld worden 
bij het stellen van de diagnose van gastro-intestinale tumoren. Momenteel is een 
combinatie van echografie en endoscopie, afhankelijk van de plaats van de tumor, de 
meest geschikte beeldvormingsmethode.  
De nieuwe modaliteiten nemen de plaats in van de arbeidsintensieve radiografische 
contrastonderzoeken. CT en MRI kunnen eveneens nuttige informatie opleveren, 
maar hun gebruik blijft voorlopig beperkt.  
 
In Hoofdstuk II worden de wetenschappelijke doelstellingen van dit werk 
voorgesteld. De uiteindelijke doelstelling van deze doctoraatsverhandeling is het 
verwerven van nieuwe inzichten met betrekking tot de diagnose van GI tumoren bij 
honden en katten.  
In het eerste deel van dit werk, wordt de rol van een proteïne, Receptor tyrosine-
proteïne kinase erbB-2, ook wel gekend als HER2, als mogelijke biomerker voor GI 
tumoren onder de loep genomen. In het tweede deel wordt de enzymatische activiteit 
van LDH in tumoren vergeleken met die in inflammatoire processen. In het derde deel 
worden de haalbaarheid, het nut en de mogelijkheden van een nieuwe 
beeldvormingsmethode, helicale hydro-CT beoordeeld.  
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Het belang van de EGFR/HER-2/KRAS signalisatie pathways bij maagtumoren, 
wordt onderzocht in Hoofdstuk III. Neoplasie van het maagepitheel bij honden (5 
adenomen en 14 carcinomen) werd retrospectief beoordeeld voor EGFR/HER-2 
immuunhistochemische expressie en KRAS mutatiestatus. Een hoge expressie van 
EGFR en HER-2 bij tumoren van het maagepitheel bij honden werd vastgesteld, 
wijzend op een mogelijke rol van deze receptoren in de carcogenese. Bijkomend werd 
een significant hoger percentage van EGFR-positieve gevallen gevonden bij 
intestinale carcinomen. In tegenstelling tot bij mensen, werd een relatie tussen de 
merker expressie en de anatomische locatie of het biologische gedrag van de tumoren 
niet geobserveerd. Tot slot werd een codon 12 mutatie in het KRAS-gen 
geïdentificeerd, gelijkaardig aan wat gevonden wordt bij humane maagcarcinomen, 
erop wijzend dat deze aangepaste pathway mogelijk een rol speelt in de pathogenese 
van maagkanker bij honden.  
 
In hoofdstuk IV wordt het mogelijke gebruik onderzocht van een toename van het 
totale LDH in het serum bij katten om te differentiëren tussen GI lymfomen en niet-
neoplastische GI aandoeningen, zoals IBD. Een prospectieve, niet-gerandomiseerde, 
gecontroleerde studie werd uitgevoerd in de reële setting van drie Italiaanse private 
diergeneeskundige klinieken. Eenenzeventig katten van cliënten (33 lymfomen, 38 
IBD) werden gebruikt. Het totale LDH in het serum werd gemeten. Hoewel 
abnormale totale LDH serumwaarden werden gemeten bij de initiële screening van de 
katten met GI lymfoom vergeleken met IBD, vertoonde deze test een slechte 
diagnostische accuraatheid bij het differentiëren tussen beide condities in de 
populatie. Anderzijds, vertoonde de studie een goede accuraatheid (meer dan 80%) 
van thet totale LDH in het serum voor het differentiëren tussen GI lymfomen en IBD 
bij gecastreerde katers en katten tot 8 jaar oud, zelfs indien de diagnostische waarde 
van LDH bijkomende studies behoeft, gezien de geringe omvang van de steekproef.  
 
In Hoofdstuk V wordt de techniek van helicale hydro-CT beschreven en 
geoptimaliseerd voor toepassing op honden en katten. De toepasbaarheid van deze 
techniek voor patiënten, verdacht van een maagtumor, wordt beoordeeld. Negen 
gezonde, vrouwelijke hondenkruisingen en twee gezonde, vrouwelijke kortharige 
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katten (DSH) werden hiervoor bestudeerd. Na de studie van de normale dieren, 
ondergingen 14 volwassen honden en 4 volwassen katten, met een bevestigde (n=11) 
of een verdenking van (n=7) maagneoplasie, een helicale hydro-CT. De conclusie was 
dat een helicale hydro-CT vrij eenvoudig uit te voeren is en nuttig kan zijn voor de 
diagnose van maagtumoren bij honden en katten. De aanbevolen dosis water is 30 
ml/kg, en de helicale hydro-CT-studie dient gevolgd te worden door de intraveneuze 
toediening van een contrastmedium. Voldoende distentie van de maag en optimaal 
getimede intraveneuze toediening van het contrastmedium zijn vereist om 
hoogkwalitatieve beelden te bekomen en om het ziekteproces naar behoren te 
detecteren en typeren.  
 
Hoofdstuk VI bevat de discussie en het besluit van dit werk. Ondanks enkele 
beperkingen, heeft deze studie het potentieel aangetoond van verschillende 
benaderingen om onze diagnostische capaciteiten te verbeteren, hetgeen nieuwe 
perspectieven biedt voor de prognose en therapie bij patiënten met GI tumoren.
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